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ABSTRACT 
The role of articular cartilage is providing a painless and attrition-free surface for 
joints movements. Osteoarthritis (OA) is a debilitating multifactorial pathology 
characterized by progressive articular cartilage loss, exposition of the bone 
surface accompanied by pain, and final loss of joint functions. To date there is 
not an effective alternative to surgical replacement of damaged joints. 
Metalloproteinases (MPs) play an important role in cartilage remodelling both in 
physiological and pathological conditions. Among the metalloproteinases, the 
aggrecanase family was shown to be the major family responsible for aggrecan 
breakdown, while matrix metalloproteinases (MMPs) target preferentially the 
collagen molecules. Tissue inhibitor of metalloproteinases (TIMPs) are the 
endogenous regulators of those enzymes and in particular TIMP-3 was found to 
possess the broadest activity. So far all synthetic MP inhibitors failed in trials for 
OA treatment, and TIMP-3 may prove to be a possible alternative. Notably 
several synthetic mutants were generated to restrict its activity towards 
metalloproteinases. 
In order to test the potential therapeutic effects of these proteins, I decided to 
employ transgenic overexpressing mice. However I appreciated that it is of 
paramount importance to restrict the exogenous expression just to cartilage. 
Moreover because it was previously observed that overexpression of TIMP-3 in 
cartilage severely affects bone development and caused embryonic lethality, I 
decided to generate tissue specific inducible transgenic mice. I focused on the 
Aggrecan promoter in order to achieve specific cartilage expression and the 
Cre/loxP system to obtain inducible expression. 
Here I show the design and generation of a new aggrecan-driven Cre deleter 
mouse line. These mice can effectively target floxed genes in cartilage. I also 
show the generation of inducible TIMP-expressing mouse lines for both a 
cartilage-specific and ubiquitous expression. 
I aim to induce OA in those transgenic mice, after induction of TIMPs 
expression, to evaluate the inhibitors role in OA treatment. 
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1.1 Synovial Joint 
1.1.1 Overview 
The term “synovial joint” refers to a structure constituted of two bone ends 
coated with a thin and smooth layer of hyaline cartilage, enclosed by the synovial 
membrane in a capsule. 
The synovial membrane or synovium lines the inside of the joint capsule and is 
responsible for producing the synovial fluid and offering physical protection. The 
synovium acts like a sieve allowing water, small molecules and nutrients to pass 
from the vascular system into the joint cavity but blocking the movement of 
larger molecules and potentially dangerous microorganisms. The resident cells of 
the synovium are the synoviocytes; these cells actively secrete proteins such as 
collagen, fibronectin and hyaluronan (HA) (which confers viscosity and 
elasticity) into the joint cavity. 
Hyaline cartilage functions as a low-friction, wear-resistant tissue designed to 
bear and distribute loads. It is a highly specialized tissue with unique mechanical 
behaviour and poor regenerative capacities. Articular cartilage has low metabolic 
activity; it consists of chondrocytes and a dense extracellular matrix composed 
primarily of water, collagen, and proteoglycan. A peculiar feature of articular 
cartilage is the lack of vascularization and innervation (Poole 1997) . 
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Figure 1.1. Schematic representation of the synovial joint. The diarthrodial joint connects two 
bones and allows their reciprocal movement. A layer of articular cartilage covers the two bony 
epiphyses. The joint cavity, containing the synovial fluid, separates the two edges 
(http://classes.midlandstech.edu/carterp/Courses/bio110/chap06/figure_08_03_labeled.jpg). 
1.1.2 Formation and structure of the synovial joint 
In vertebrates the synovial joint is a rather remarkable structure that can be 
heavily specialized depending on location and function. Examples are the joints 
of the femur head that is encapsulated in the hips or the knee joint formed 
between femur and tibia bones. Although the macroscopic mechanism of joint 
formation is a quite linear process, however how mesenchymal cells are directed 
to form an interzone and how the interzone differentiates into distinct joint 
components are largely unknown. Research focused to uncover the molecular 
mechanisms is of importance to understand, and possibly cure, both congenital 
diseases (e.g. several types of chondrodysplasia), and pathological conditions 
related to aging that leads to progressive degeneration and loss of function of the 
joint, as in osteoarthritis (OA). 
The first event in vertebrate skeleton generation is the mesenchymal cells 
condensation in a continuous structure (Figure 1.2). Individual skeletal elements 
then arise through a segmentation process, introducing joints in specific 
locations. The first sign of the joint development is observed with the appearance 
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of the interzone where the joints will form. The interzone is recognized as an area 
where the mesenchymal cells are closely connected by gap junctions suggesting a 
strong coordination among them. Interzone can be structurally divided into three 
sub-structures: a central intermediate zone that separates two outer layers. While 
mesenchymal cells from outer layers seem to differentiate into chondrocytes and 
become part of the epiphyses, the intermediates zone will form the proper 
articular cartilage. The formation of the interzone is a process independent from 
the skeletal formation, as demonstrated by Pacifici and colleagues (Pacifici, 
Koyama et al. 2006). If the mesenchymal cells from the presumptive interzone of 
the elbow are removed from during embryogenesis, it prevents the joint 
formation, but the bones will still be formed (Holder 1977) . The first step in joint 
formation is cavitation, an event caused mostly by apoptosis of pre-chondrocytes 
in the presumptive joint region (Archer, Dowthwaite et al. 2003) . The pre-
chondrocytes, aligned underneath, differentiate into articular chondroblasts that 
express high level of lubricin and matrix protein. Morphological observations 
indicate that once the joint anlages have separated, those cells flattened and form 
the articular chondrocytes of the articular cartilage layer (Figure 1.2). The 
mechanism coordinating this event is not fully defined, but is likely to involve 
changes in ECM composition (Pitsillides, Archer et al. 1995, Capehart 2010). 
Studies suggest that enzymatic degradation of the ECM is unlikely (Edwards, 
Wilkinson et al. 1996), but support a selective mechano-dependent activation of 
the MEK–ERK pathway, leading to local changes in hyaluronan synthesis and 
binding in cells immediately bordering the presumptive joint, which directly 
contribute to the loss of tissue cohesion essential for cavitation (Bastow, Lamb et 
al. 2005). The articular chondrocytes are resting cells and maintain high 
expression of cartilage genes such as Aggrecan (Acan), Lubricin (Prg4) and basal 
level of type II collagen (Col2a1). 
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Figure 1.2. Schematic diagram illustrating the major steps in synovial joint formation. A: 
Mesenchymal condensations produce an uninterrupted layer in the early limb bud. B: Unknown 
upstream patterning mechanisms determine the exact location for joint initiation. C: Further 
condensation marks the forming interzone; mesenchymal cells constituting the bulk of the 
condensations differentiate into chondrocytes. D: A cavitation process begins and eventually 
leads to the physical separation of the adjacent skeletal anlagen and formation of a synovial 
cavity. E: The opposing sides of the joint begin to be molded into reciprocally shaped and 
interlocking structures. F: All the distinct component of a mature joint form and include 
articular cartilage, capsule and the synovial cavity. (Adapted from Pacifici et al., 2005). 
On the molecular level SOX9 plays a central role in chondrocyte differentiation 
and commitment. Sox9 is a member of the SRY (sex-determining region of the 
Y-chromosome) family that contains the HMG (high mobility group) box DNA-
binding domain. Targeted loss of SOX9 in mouse early development results in 
complete absence of both cartilage and bone, whereas SOX9 inactivation at later 
stages leads to diminished chondrocyte proliferation, chondrodysplasia and joint 
formation defects (Bi, Deng et al. 1999). SOX9 was observed to activate the 
expression of type II collagen in mouse embryos from 10 dpc (day post coitum) 
(Lefebvre, Huang et al. 1997), explaining the parallel expression pattern of the 
two genes (Zhao, Eberspaecher et al. 1997). More recently it was shown that 
SOX9, in concert with L- SOX5 and L- SOX6, recognizes a target sequence 
upstream of the Acan enhancer and drives its expression in cartilage (Han and 
Lefebvre 2008). Sox9 expression persists postnatally and in adult mice to control 
the homeostasis of connective tissues such as the growth plate, articular cartilage, 
and the intervertebral disk (Henry, Liang et al. 2012). SOX9 coordinates not only 
the expression of extracellular matrix genes, but is required to maintain 
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chondrocyte columnar proliferation and generate cell hypertrophy, two key 
features of functional growth plates. Sox9 may be critical to shift the activities of 
Runx2 and β-catenin from osteoblast differentiation to chondrocyte maturation, 
inhibiting not only progression from proliferation to pre-hypertrophy, but also 
subsequent acquisition of an osteoblastic phenotype. SOX9 protein outlives its 
mRNA in upper hypertrophic chondrocytes, where it contributes with MEF2C to 
directly activate the major marker of these cells, Col10a1 (Dy, Wang et al. 2012). 
Moreover SOX9 was observed during attempted repair of articular cartilage 
damage in a transgenic mouse model of osteoarthritis (Salminen, Vuorio et al. 
2001). 
Targeting of Sox9 in mouse chondrocytes leads to down-regulation of the levels 
of expression of Ihh (Indian Hedgehog) and its two downstream targets 
parathyroid hormone receptor protein genes (PTHrP) (Akiyama, Chaboissier et 
al. 2002). Both Ihh and PTHrP are expressed postnatally by chondrocytes and are 
essential for maintaining the growth plate physiology (Maeda, Nakamura et al. 
2007) and are shown to play a role in cartilage repair and pathological conditions 
(Kudo, Mizuta et al. 2011).  
Wnt/β-catenin signalling is also essential in chondrocyte proliferation, 
differentiation and apoptosis during development (Hartmann and Tabin 2000). 
The critical role of Wnt/β-catenin signalling has been elegantly demonstrated in 
the cartilage of adult mice in which the gene for β-catenin was selectively 
activated in articular chondrocytes and shown to produce premature chondrocyte 
differentiation and an OA-like phenotype (Zhu, Tang et al. 2009) .  
Two genes encoding secreted proteins, Wnt9a and Gdf5, have been shown to 
play important roles in early joint formation, both position and cavitation. It has 
been shown that isolated interzone cells expressed typical phenotypic markers, 
such as GDF-5, WNT-9A and CD-44, and differentiated into chondrocytes over 
time (Pacifici, Koyama et al. 2006). Although evidence from Wnt9a null mice 
suggests that it does not initiate joint cavity formation, it is important in 
specifying joint position. Misexpressing Wnt9a locally within the developing 
autopods of chick embryos leads to alterations of the skeletal pattern (Hartmann 
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and Tabin 2001) . Wint9 can activate expression of CD44 mRNA, the major 
hyaluronan-binding protein, in knee joint, thus demonstrating a role in joint 
cavitation (Dowthwaite, Edwards et al. 1998).  WNT-9A was shown to induce 
expression of Gdf5, a member on the TGFβ super-family. Gdf5 is required for 
the normal formation of a number of joints is not sufficient to initiate the joint-
forming process. A loss-of-function mutation of the Gdf5 gene causes the loss of 
several joints in mice (Storm, Huynh et al. 1994). Similarly, a truncated GDF5 
protein in humans is known to cause a congenital joint malformation called 
Grebe-type chondrodysplasia (Basit, Naqvi et al. 2008). However, gain of 
function of Gdf5 does not result in joint formation in the developing limb 
(Tsumaki, Nakase et al. 2002). 
 
1.1.3 Hyaline cartilage composition 
Hyaline cartilage lacks neural, vascular and lymphatic structures (Buckwalter and 
Mankin 1997). Articular chondrocytes contribute only 1–5% to the total volume 
of the articular cartilage. These receive their nutrition by diffusion through the 
abundant extracellular matrix (ECM). ECM has a slightly basic pH, changes in 
which can easily disrupt the highly specialized matrix infrastructure. 
Chondrocytes are very specialized cells responsible for synthesizing and 
maintaining the surrounding ECM (Chen, Frenkel et al. 1999) . 
The articular cartilage can be divided into three components: water, collagens, 
and proteoglycans.  
Water provides about 65-80 % of the wet weight of the cartilage. Such amount of 
water is contained in the intrafibrillar space produced by the ECM components, 
and held in place by the negative charges on the proteoglycans. Such amount of 
water helps to maintain the compression-resistance ability to the tissue. Moreover 
it helps to generate a low-friction surface and provides nutrition the articular 
chondrocytes. 
Collagens form 10–20% of wet weight of the articular cartilage. Type II collagen 
is the principal component (90–95%) of the macrofibrillar meshwork, provides 
the tensile strength of the articular cartilage, and is produced by proliferating 
chondrocytes. Type VI collagen is found in the pericellular space and helps 
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chondrocytes to attach to the matrix. Type X collagen provides structural support, 
aids in cartilage mineralization and is associated to the hypertrophic 
chondrocytes.  
Proteoglycans account for 10–20% of the wet weight and provide compressive 
strength to the articular cartilage, and maintain the fluid electrolyte balance. They 
are heavily glycosylated proteins and consist of a "core protein" with one or more 
covalently attached glycosaminoglycan (GAGs) chains. GAGs are long un-
branched polysaccharides, consisting of a repeating disaccharide unit. Being 
overall highly polar they attract local water molecules, generating an increment in 
osmolarity that lead to an increase of the concentration of inorganic ions (e.g. 
sodium) inside the matrix. In articular cartilage, the chief structural proteoglycan 
is aggregan, which consists of a long protein core with up to 100 chondroitin 
sulphate chains and up to 50 keratan sulphate glycosaminoglycan chains. 
Aggregan molecules bind via a link protein on the protein core to a hyaluronate 
molecule. In cartilage, the hyaluronate molecules form a backbone with 
palisading aggrecan molecules; this macromolecular complex is known as the 
proteoglycan aggregate. The interaction between the proteoglycan molecules and 
collagen fibrils creates a fibre-reinforced composite solid matrix. The 
proteoglycans are entangled and compacted within the collagen interfibrillar 
space, which helps to maintain a porous-permeable solid matrix and determines 
the movement of the fluid phase of the matrix. 
Finally chondrocytes are the cartilage resident cells. They are high specialized 
cell type and responsible of deposition of both collagens and proteoglycans. 
Because the relatively low cell number compared to the total volume of the 
tissue, chondrocytes are characterized by the lack of cell-to-cell interactions, and 
receive their nutrition by diffusion from blood vessels at the periphery of the 
tissue. In mammals such human chondrocytes survive on low oxygen conditions 
depending on anaerobic metabolism, however in smaller animals such mouse the 
hypoxic environment is absent. Finally articular chondrocytes produce the 
enzymes responsible for the matrix degradation. 
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1.1.4 Hyaline cartilage ultra-structure 
Cartilaginous tissues are present throughout the body and are classified into three 
groups: hyaline, elastic and fibrocartilage cartilage according to the composition 
of the extracellular matrix (ECM) and on tissue morphology (Bhosale and 
Richardson 2008) . Articular cartilage is a hyaline cartilage and has an organized 
layered structure that can be functionally and structurally divided into four zones: 
the superficial zone, the middle (or transitional) zone, the radial (or deep) zone, 
and the calcified zone. These zones are each characterised by different amounts 
and organisation of matrix macromolecules (Figure 1.3).  
The superficial zone is the articulating surface that provides a smooth gliding 
surface and resists shear. It has the highest collagen content of the zones, and the 
lowest in proteoglycan; the collagen fibrils in this zone are densely packed and 
have a highly ordered alignment parallel to the articular surface (Mow, Proctor et 
al. 1989). Chondrocytes in the superficial zone are elongated and express proteins 
that have lubricating and protective functions and secrete relatively little 
proteoglycan. The middle zone covers the majority of the articular cartilage 
volume. Collagen fibres in this layer are less organized, loosely packed, and 
aligned obliquely to the surface (Hwang, Li et al. 1992). Chondrocytes are more 
rounded than in the superficial layer and arranged vertically into columnar 
clusters. The deep zone makes up to a third of the cartilage volume and consists 
of large diameter collagen fibrils oriented perpendicular to the articular surface. 
This layer contains the highest proteoglycan and lowest water concentration. The 
chondrocytes are arranged, as in the layer above, in columnar clusters parallel to 
the collagen fibres and perpendicular to the joint line. The calcified cartilage zone 
separates hyaline cartilage from subchondral bone. A discrete band marks the 
physical boundary with the deep layer.	This line represents the mineralization 
front of the calcified cartilage and provides a gradual transition between the two 
dissimilar regions of cartilage (Lyons, Stoddart et al. 2005). It has an affinity for 
numerous histological stains and appears as the ‘‘tidemark’’ in haematoxylin 
sections. The calcified cartilage contains large amount of type X collagen and 
small cells in a chondroid matrix speckled with apatite salts. 
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Figure 1.3 Architectural layout of the articular cartilage. Schematic representation of articular 
cartilage ultrastructure. (Adapted from Sopena-Juncosa et al., 2000). 
1.2 Homeostasis of the Cartilage ECM 
1.2.1 Overview 
In cartilage, water molecules are attracted and maintained by the negatively 
charged proteoglycans. Both proteoglycans and collagens are synthetized and 
deposited by chondrocytes. Among collagens the type II is the most abundant and 
interestingly is deposited quite early during tissue development, remaining 
virtually stable during the life of the organism. Proteoglycans on the other hand 
are subjected to a continuous remodelling, with new molecules actively 
synthetized. The turnover of those structural proteins is maintained by a balance 
between their synthesis and the production of matrix proteinases that can be 
divided into: matrix metalloproteinases (MMPs), a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTSs), a disintegrin and 
metalloproteinase (ADAMs). These enzyme share sequence and structure 
similarity but differ for specificity of substrate. Chondrocytes maintain such 
balance between catabolic and anabolic activity using the tissue inhibitors of 
metalloproteinase (TIMPs). These secreted protein are the endogenous regulators 
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of the matrix enzymes and their misregulation can lead to development defect as 
well as pathological conditions. 
 
1.2.2 Proteoglycans and glycosaminoglycans 
The study of cartilage proteins composition proved to be a very difficult task, 
because the strong interactions between the charged molecules of this tissue. 
Extraction and purification of the single components required harsh conditions 
that were matched only with the use of the strong chaotropic agent guanidinium 
hydrochloride and CsCl density gradient centrifugation.  
Proteoglycans are heavily glycosylated proteins consisting of a unit called “core 
protein” decorated with one or more chains of glycosaminoglycans (GAGs). 
GAGs are covalently linked to serine residues of the core protein; they are 
polysaccharides consisting of a repeating disaccharide that contains an amino 
sugar. GAGs are negatively charged and this is essential for their function. 
Proteoglycans are found in all connective tissues, extracellular matrix and on the 
surfaces of many cell types. They are remarkable for their diversity such as 
different cores, different numbers of GAGs with various lengths and 
compositions). The protein component of proteoglycans is synthesized by 
ribosomes on the rough endoplasmic reticulum. Glycosylation occurs in the 
Golgi apparatus in multiple enzymatic steps. First a special link tetrasaccharide is 
attached to a serine side chain on the core protein to serve as a primer for 
polysaccharide growth. Then sugars are added one at a time by glycosyl 
transferase. The completed proteoglycan is then exported in secretory vesicles to 
the extracellular matrix of the tissue. 
Although cartilage ECM is made by of several proteoglycans, aggrecan is by far 
the main one and contributes 90% of the total proteoglycan content. In the 
cartilage ECM aggrecan is bound to a backbone of hyaluronan (hyaluronic acid) 
and forms huge aggregates (up to 20 aggrecan molecules) filling the interfibrillar 
space of the cartilage matrix (Hardingham 1979, Roughley 2006). The 
hyaluronan backbone is itself anchored to chondrocytes via CD44. Aggrecan is 
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connected to the hyaluronan by a globular protein, highly homologous to the 
aggrecan globular domain and named link protein. 
 
Figure 1.4. Schematic diagram illustrating general proteoglycans structure and GAGs 
interaction. Proteoglycans are a class of extracellular proteins composed of a core protein (shown 
in blue) and distinguished by the addition of glycosaminoglycans (GAGs). GAGs are long-chain 
polysaccharides composed of disaccharide repeats. Here is schematised hyaluronate composed of 
the repeating disaccharide pair gluronic acid (GlcUA, purple) and N-acetylglucosamine (GlcNAc, 
green). 
1.2.3 Aggrecan 
1.2.3.1 Aggrecan gene and expression 
The aggrecan gene (ACAN) has been characterised in several species including R. 
norvegicus (Doege, Sasaki et al. 1990), H. sapiens (Valhmu, Palmer et al. 1995) 
(Valhmu, Palmer et al. 1995), M. musculus (Watanabe, Gao et al. 1995), and G. 
domesticus (Li and Schwartz 1995). In human aggrecan gene has been localised 
to chromosome 15q26.2 by in situ hybridization (Korenberg, Chen et al. 1993) 
(Korenberg, Chen et al. 1993) and sequencing has revealed that the gene consists 
of 19 exons and 18 introns. 
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Aggrecan gene is mainly expressed in cartilaginous tissue; expression can be 
found in differentiatied chondrocytes such as the chondrocytes of the growth 
plate and the articular cartilage, since embryonic stages and throughout 
adulthood. However is not expressed in skeletogenic mesenchymal cells, the 
perichondrium or the presumptive joint cells (Shepard, Krug et al. 2007). 
Aggrecan gene is also expressed in the fibrocartilage of the menisci. Notably 
although the expression of aggrecan is mainly found in differentiated 
chondrocytes, it can be detected before the appearance of cartilage matrix. 
Aggrecan mRNA was detected in E14.5 mice in aggregation of mesenchymal cell 
before chondrogenesis (Fukada, Shibata et al. 1999).  
Aggrecan mRNA has also been observed in the in non-cartilage tissues such as 
central nervous system (CNS), liver, adipose tissue and heart. In CNS aggrecan is 
the major constituents of perineuronal nets in adult rat brain. Matthews et al 
showed that neurons are the predominant cellular source of aggrecan in the adult 
CNS. Using in situ hybridization they also demonstrated that aggrecan mRNA is 
not expressed in the CNS until late in embryonic development, with peaks in 
expression at 1 month of age, followed by stable expression during adulthood 
(Matthews, Kelly et al. 2002). More recently was found that aggrecan regulates 
astrocyte development and is expressed by embryonic glial precursors 
(Domowicz, Sanders et al. 2008). In liver aggrecan mRNA has been shown to be 
expressed during liver fibrogenesis (Krull and Gressner 1992). In adipose tissue 
Voros et al showed that aggrecan mRNA is present in murine intra-abdominal 
and inguinal subcutaneous fat pads. They suggested that aggrecan might 
contribute to the regulation of lipid uptake and obesity in mice (Voros, Sandy et 
al. 2006). Studies of chicken embryo hearts at stages 12-21 of development, 
shown that aggrecan is specifically co-localized with several groups of migrating 
cells that such as endocardial cushion tissue cells, epicardial cells and a 
mesenchymal cell population in the inflow tract (Zanin, Bundy et al. 1999). The 
aggrecan-like molecules that are expressed in such different tissues are all 
products of the same gene. However, in each tissue the gene product exhibits 
significantly different chemical and structural properties, indicating that although 
they share an identical core protein, they are processed differently, yielding to 
distinct proteoglycans (Schwartz and Domowicz 2004). 
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The promoter of the aggrecan gene has been studied in different species including 
H. sapiens (Valhmu, Palmer et al. 1995) and R. norvegicus (Doege, Garrison et 
al. 1994). In humans, the basal promoter was shown to lack canonical TATA and 
CAAT boxes and contain several putative binding sites for ubiquitous 
transcription factors such as SP-1, AP-2, and AP-4 that are located in both the 
promoter and untranslated regions. Those alone or in combination may mediate 
the basal activities of this promoter. Cis and trans-regulatory elements have been 
also identified by in vitro studies and have been shown to regulate the expression 
of aggrecan by directly driving/repressing promoter activity. The first in vivo 
study to search for these regulatory elements involved the rat aggrecan gene. 
Initially, this search had focused primarily on a 922 bp DNA fragment across the 
proximal promoter. This sequence had showed higher promoter activity in 
transfected chondrocytes than in fibroblasts (Doege, Garrison et al. 1994). 
However it was predicted that there might be additional regulatory sequences 
other than the proximal promoter that are responsible for expression of the rat 
aggrecan gene in chondrocytes. Attention was focused on a 30 kb DNA fragment 
that span upstream of the TSS (transcription start site) and throughout the first 
intron, employing both cell transfection assays as well as transgenic mice. 
Experimental results in cell transfection experiments identified an upstream 5kb 
tissue specific enhancer/repressor at about 10 kb upstream of the TSS. This 
upstream enhancer was active also in vivo when fused to a proximal promoter 
sequence (Doege, Hall et al. 2002). More recently an important study on 
aggrecan cis-regulatory elements was performed by Lefevbre group. A highly 
conserved and regulatory 359-bp sequence located approximately 10Kb upstream 
of the mouse Acan TSS (partially corresponding to the sequence previously 
identified in the rat aggrecan gene) was identified. Four tandem repeats of this 
sequence were able to direct expression of a Col2a1 minimal promoter in both 
embryonic and adult cartilage in transgenic mice, in a manner that matches 
aggrecan expression. Expression levels in transient transfection experiments 
shown that the identified sequence was almost as active as proper the Col2a1 
enhancer fused to the Col2a1 minimal promoter (Han and Lefebvre 2008) . These 
findings lay the path to my present work. Harnessing aggrecan gene enhancer 
sequence I could achieve strong and stable expression of target genes in cartilage. 
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1.2.3.2 Aggrecan protein 
The core protein of aggrecan has a molecular weight of ~230 kDa and consists of 
three globular domains, G1, G2 and G3, and three interglobular domains, the 
keratan sulphate (KS) and chondroitin sulphate (CS) glycosaminoglycan 
attachment domains located between G2 and G3 and a short interglobular domain 
between G1 and G2. The N-terminus comprises the G1 globular domain, which 
interacts with hyaluronan and link protein. Because G1 domain is important for 
interaction with hyaluronan, aggrecan which lacks in the G1 domain, is free to 
exit the matrix and does not contribute to cartilage function (Sandy, Neame et al. 
1991). Mild trypsin treatment generates a protein fragment containing the G1 and 
G2 domains, which retains hyaluronan binding capacity, and thus is termed the 
hyaluronan-binding region (HABR). The C-terminus comprises the G3 domain 
that includes an EGF module, a C-type lectin module and a complement 
regulatory protein (CRP) module. Deposition of aggrecan is a hallmark of 
chondrogenesis. Aggrecan has a relatively long half-life of about 3-4 years, and 
thus its expression in maintained in adult articular chondrocytes. It has been 
shown that this protein is cleaved by endogenous proteinases in specific sites 
between G1 and G2 domains. In particular cleavage occurs in the IGD domain at 
Glu373-Ala374 (by ADAMTS) and at Asn341-Phe342 (by MMPs) (Sandy, Flannery 
et al. 1992, Fosang, Last et al. 1993). Other cleavage sites were found using in 
vitro studies but are unlikely to be responsible for aggrecan degradation in 
physiological conditions. Other less abundant small proteoglycans found in the 
matrix include decorin, biglycan, lumican and fibromodulin which are thought to 
be involved in fibril assembly, organisation and stabilisation of collagen matrix 
structure within the cartilage extracellular matrix (Roughley 2006). 
 
1.2.4 Collagens 
Collagen is the main component of connective tissues such as the cartilage and 
bone, and is the most abundant protein type in the vertebrate organism. The 
formation of collagen-rich extracellular matrices is a complex process that 
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involves intracellular and extracellular steps. Mutations in genes that encode 
individual chains of triple-helical collagens present in bone and cartilage are 
associated with heritable diseases of skeletal tissues. In addition, mutations in 
genes encoding proteins involved in the intracellular and extracellular 
modifications of collagens are also responsible for developing skeletal 
abnormalities (Arnold and Fertala 2013). Mutations in the COL2A1, the gene 
that encodes collagen II, are associated with spondyloepiphyseal dysplasia 
(SED), characterized by short stature, myopia, and hearing loss (Royce and 
Steinmann 2003, Kannu, Bateman et al. 2012). Collagens fibres are deposited 
early during development and provide tensile strength to the cartilage.  
The collagen molecule is composed of a triple helix that may consist of 
heterotrimer (two identical chains and an additional chain that differs slightly in 
its chemical composition, eg [α1]2(α2)) or homotrimer (eg. [α1]3). Each chain 
consists of approximately 300 uninterrupted tandem repeats of -Glycine-X-Y- 
triplets (where X and Y positions are frequently occupied by proline or 
hydroxyproline residues). Collagen type I and II are produced as pro-collagens, 
in which the extended triple-helical domains are flanked by globular N-terminal 
and C-terminal pro-peptides, this feature prevents that helices interact too early 
and engulf the cell machinery. As a simultaneous process with the biosynthesis 
and post-translational modifications in the ER, the nascent pro-collagen α-chains 
fold into the triple-helical structure in a zipper-like fashion (Engel and Prockop 
1991). This occurs via site-specific interactions of domains present within the C 
pro-peptide, which align individual pro-collagen chains and initiate their folding. 
Type II collagen is the most abundant collagen in articular cartilage, reaching the 
90% of the total amount. It is made by a homotrimer of α1 chains, coded in 
human by the COL2A1 gene. It has been demonstrated that the gene undergoes 
alternative splicing, and two forms are expressed in progenitor cells during early 
embryo development, and in fully differentiated chondrocytes (Mcalinden, 
Johnstone et al. 2008). Type II collagen is a very stable molecule and therefore it 
is believed that the synthesis of type II collagen in articular cartilage is down-
regulated after development and maintained to basal levels during adulthood. 
However there are evidences that transcription levels may be upregulated in 
osteoarthritis (Hermansson, Sawaji et al. 2004). 
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In addition to type II collagen in cartilage other types are present and necessary to 
maintain the tissue homeostasis. Type VI collagen has been identified in the 
pericellular matrix of articular cartilage, but its role is unknown but it may 
interact with matrix proteoglycans (Soder, Hambach et al. 2002). Type IX 
collagen decorates type II fibrils allowing cross-linking the adjacent ones. It is 
thought that type IX role is to increase network mechanical integrity and 
providing a restraint for entrapped proteoglycan osmotic swelling pressure. Type 
X collagen is a homotrimer that is highly expressed by hypertrophic 
chondrocytes within the calcified cartilage (Gannon, Walker et al. 1991, Nerlich, 
Kirsch et al. 1992). Type XI collagen is thought to reside in the central portion of 
the collagen fibril, acting as a filamentous core template which regulates fibril 
diameter through its retained N-propeptide domains (Sandberg, Hirvonen et al. 
1993). 
1.3 Cartilage metalloproteinases 
1.3.1 Overview 
Physiological remodelling processes such as development, morphogenesis and 
tissue repair involve precisely regulated degradation of the ECM. Remodelling 
also occurs during the course of diseases such as arthritis, cancer and 
cardiovascular disease, in part in an attempt at repair, but is frequently 
deregulated and destructive (Sternlicht and Werb 2001, Milner and Cawston 
2005, Aiken and Khokha 2010). Although members of four classes of 
proteinases: serine/threonine proteinases, cysteine proteinases, aspartic 
proteinases, and metalloproteinases, have been implicated in the degradation of 
cartilage, current data indicate that the initial steps in matrix breakdown are 
extracellular processes involving metalloproteinases. 
1.3.2 Matrix Metalloproteinases 
In human 23 different MMPs are synthetized; these enzymes are defined as 
multidomain zinc metalloproteinases, because they possess a catalytic domain 
that contains the Zn2+ binding motif HEXXHXXGXXH, that is essential for their 
activity (Bode, Gomis-Ruth et al. 1993). Most of MMPs require Ca2+ ions to 
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exert their activity; in fact chelating agents that remove such co-factors can 
inhibit the enzyme activity. MMPs generally consist of a pro-domain, a catalytic 
domain, a hinge region, and a hemopexin domain. The matrixins are synthesized 
as pre-proenzymes and the signal peptide is removed during translation to 
generate proMMPs. The pro-peptides have the ‘cysteine switch’ motif 
PRCGXPD in which the cysteine residue coordinates with the catalytic Zn2+ in 
the catalytic domain, keeping the proMMPs inactive (Van Wart and Birkedal-
Hansen 1990). However it was observed in vitro that some chemical agents may 
lead to activation (Nagase 1997). Notably among them thiol-modifying agents, 
oxidized glutathione, SDS (sodium dodecyl sulphate), chaotropic agents and 
reactive oxygens.   These agents most likely work through the disturbance of the 
cysteine-zinc interaction of the cysteine switch (Van Wart and Birkedal-Hansen 
1990). MMPs are either secreted from the cell or anchored to the plasma 
membrane. On the basis of substrate specificity, sequence similarity, and domain 
organization, vertebrate MMPs can be divided into six groups: collagenases, 
gelatinases, stromelysins, matrilysins, membrane-type (MT-MMPs) and others 
(Visse and Nagase 2003, Parks, Wilson et al. 2004, Murphy and Nagase 2008). 
Belong to collagenases MMP-1, -8 and -13; these enzymes are able to cleave 
interstitial collagens types I, II, and III at specific site, but they can also digest 
other ECM molecules. MMP-13 in particular preferentially cleaves the type II 
collagen, that is the major collagen constituent of cartilage. MMP-2 and MMP-9, 
also referred as gelatinase A and B, can digest already denatured collagens, so 
they may act in concert with collagenases during cartilage breakdown. Substrates 
of MMP-2 are collagens type I, II and III (Aimes, French et al. 1994). Belong to 
the stromelysins MMP-3 and MMP-10; these enzymes are characterized by a 
broad substrate specificity being able to degrade many of the extracellular matrix 
proteins such as: gelatins, proteoglycans, fibronectin, and type IX collagen. 
Moreover MMP-3 is involved in the protolithic activation of other MMPs 
(Suzuki, Enghild et al. 1990). The matrilysins (MMP-7 and -26) are characterized 
by lack of the hemopexin domain (Uria and Lopez-Otin 2000). Both enzymes 
digest ECM components but also cell surface molecules such as: Fas-ligand, pro-
TNF-α (tumor necrosis factor-α) and E-cadherin. Membrane-type MMPs (MT-
MMPs) are subdivided into four trans-membrane proteins (MMP-14, -15, -16 and 
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-24) and two GPI-anchored (glycosylphosphatidylinositol) (MMP-17 and -25) 
proteins. These enzymes are able to digest several ECM components but also 
activate other MMPs via pro-domain cleavage. In particular MMP-14 (also know 
as MT1-MMP) can digest type I, II, and ‒III collagen (Ohuchi, Imai et al. 1997). 
Importance of this enzyme is demonstrated by the presence of skeletal 
abnormalities during postnatal development in mice mmp14 deficient 
(Holmbeck, Bianco et al. 1999).  
 
Table 1.1. Mammalian Matrix Metalloproteianses (MMPs). Adapted from (Parks, Wilson et 
al. 2004).	
The expression of matrix metalloproteinases in synovial membranes, cartilage, 
tendon and bone of synovial joints in both rheumatoid arthritis (RA) and OA is 
well documented and often correlates with tissue destruction (Murphy and 
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Nagase 2008). The collagenases MMP-1 and MMP-13 are produced by synovial 
fibroblasts, macrophages and chondrocytes and have important roles in RA and 
OA because they are able to initiate the degradation of fibrillar collagens, making 
them accessible to further degradation by gelatinases. Antibodies that recognize 
terminal amino acid sequences generated by proteolysis (known as neo-epitopes) 
at specific sites in type II collagen have been since-long used for identifying the 
proteinases responsible for cartilage breakdown both in vitro and in vivo 
(Hollander, Heathfield et al. 1994, Wu, Billinghurst et al. 2002). Preliminary 
results with quantitative assays of type II collagen neo-epitopes suggest that they 
may be useful markers of joint disease in humans (Fosang, Stanton et al. 2003). 
Interestingly MMP-13 also degrades the proteoglycan molecule, such as 
aggrecan, giving it a dual role in matrix destruction. Non-collagen matrix 
components of the joints are also degraded by MMP-2, MMP-3, MMP-9, MMP-
10 and MMP-19 (Cawston and Wilson 2006). Generally speaking alterations in 
MMPs activity were correlated to one or more human diseases; however animal 
models of human disease studied so far, demonstrated that relevance of MMP 
expression profiles varies with the nature of the cells, the stage of the disease and 
the genetic make up of the animal (Lemaitre and D'Armiento 2006, Martin and 
Matrisian 2007). Targeted gene deletion in mice has shown, with few exceptions, 
that embryogenesis and subsequent growth happens normally, suggesting a 
compensatory role of MMPs function during development. On the other hand 
tilting the balance by inducing external challenges to the systems have proved 
fruitful in understanding of the roles of MMPs. In light of those consideration is 
not surprising that only few human genetic disorders of the MMPs and TIMPs 
have been described and directly correlated to pathological conditions. For 
example it has been reported that mutations in the MMP2 gene, resulting in the 
absence of active enzyme, are linked with an autosomal recessive form of 
multicentric osteolysis (Martignetti, Aqeel et al. 2001). At the same time loss of 
MMP-2 in mice leads to defects in skeletal and craniofacial development (Mosig, 
Dowling et al. 2007). In human mutation in the MMP13 gene is correlated to a 
form of spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO)) 
characterized by defective growth and remodelling of long bones (Kennedy, 
Inada et al. 2005). Similarly mice lacking the Mmp13 gene have defects in 
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growth plate cartilage with increased hypertrophic domains and delayed 
endochondral ossification during development (Inada, Wang et al. 2004, 
Stickens, Behonick et al. 2004). 
Due to the role of MMP in pathological conditions, inhibitors of MMPs were 
investigated for therapeutic potential. MMP inhibitors can broadly be subdivided 
into non-synthetic (e.g. endogenous) or synthetic. Several potent MMP inhibitors 
have been identified, including hydroxamates, thiols, carbamoylphosphonates, 
hydroxyureas, hydrazines, β-lactams, squaric acids and nitrogenous ligands. 
Although several of these compounds shown appreciable inhibitory effects in 
vitro, most of MMP inhibitors have exhibited serious side effects during 
preclinical trials. These side effects are caused by insufficient selectivity. Several 
MMPs, for example, mediate the release of signalling molecules that where 
shown to inhibit angiogenesis and vasculogenesis in mice, such as angiostatin 
and endostatin. It is now clear that broad-spectrum inhibition of metzincins is 
inefficient for effective pharmaceutical intervention in pathological conditions 
since proteolytic products of MMPs or other metzincins are responsible for 
physiological processes. It is generally acknowledge that the bulk of inhibitor 
design efforts need to focus on the improvement of inhibitor selectivity index in 
order to obtain specific tools for probing metzincin function and develop drug-
candidates with better chances in clinical applications. The design of such 
inhibitors is a difficult task given the conserved active-site topology and among 
MMPs. However efforts in this direction have already shown results, as a 
Johnson and colleagues have recently developed a highly selective inhibitor for 
MMP-13 that effectively reduces cartilage damage in vivo. Interestingly rats do 
not develop musculoskeletal syndrome side effects. This highly selective 
inhibitor MMP-13 in may overcome the major safety and efficacy challenges that 
have limited previously tested non-selective MMP inhibitors (Johnson, 
Pavlovsky et al. 2007).  
Characteristic and therapeutic possibilities of endogenous inhibitors, TIMPs, are 
discussed in a dedicated paragraph. 
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1.3.3 A Disintegrin And Metalloproteinases with Thrombospondin Motifs 
ADAMTSs family of zinc proteins counts 19 members but only 5 were shown to 
degrade tissues proteoglycans, such as brevican, versican, decorin but also 
COMP and fibromodulin (Matthews, Gary et al. 2000, Liu, Kong et al. 2006, Liu, 
Kong et al. 2006, Apte 2009). It has been shown that some ADAMTSs are 
responsible of the aggrecan cleavage in arthritis, although with great difference in 
activity, thus some of them are also referred to as aggrecanases: ADAMTS-1, 
ADAMTS-4, ADAMTS-5, ADAMTS-8, and ADAMTS-9 (Tortorella, Burn et al. 
1999, Kuno, Okada et al. 2000). ADAMTSs structure is modular, they consist of: 
a proteinases domain containing the signal peptide, the pro-peptide and the 
catalytic site; an ancillary domain consisting of disintegrin-like module, a central 
TSR (thrombospondin repeat), a cysteine-rich module, a cysteine-free spacer, and 
a variable number of additional TSRs (Nagase and Kashiwagi 2003, Apte 2004). 
ADAMTSs share a conserved catalytic domain containing the consensus 
HEBxHxBGBxH motif, but differ in the ancillary domain, thus the latter plays a 
critical role in directing these enzymes to their substrates. Moreover C-terminal 
domain, that may contain thrombospondin motifs, interacts with the cell surface 
and the ECM (Porter, Clark et al. 2005), but it was also shown to promote 
association with N-TIMP-3, and thus contribute to the regulation process via 
endogenous inhibitors (Troeberg, Fushimi et al. 2009).  
 Aggrecanases are the main proteinases responsible for aggrecan cleavage in the 
early events of cartilage remodelling, and their activity is considered a hallmark 
of cartilage degradation during inflammatory joint diseases like OA. While Little 
and colleagues have shown that mice deficient for ADAMTS-1 are not protected 
from experimental (Little, Mittaz et al. 2005), it was demonstrated that mice 
deficient in ADAMTS-5 (but not ADAMTS-4) are protected from early aggrecan 
loss and cartilage erosion in inflammatory and non-inflammatory models of 
arthritis (Glasson, Askew et al. 2005, Stanton, Rogerson et al. 2005) . However 
was also shown that Adamts5 null mice cartilage explants if stimulated still 
release aggrecan neo-epitopes, suggesting that ADAMTS-4 is potentially able to 
digest aggrecan (East, Stanton et al. 2007).  Although some studies suggested that 
human ADAMTS-5 is substantially more active than ADAMTS-4 (Gendron, 
Kashiwagi et al. 2007, Song, Tortorella et al. 2007), it is still not clear which 
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aggrecanase plays the main role in pathological cartilage degradation. As all the 
matrix-degrading enzymes, also aggrecanases expression in tissues must be a 
regulated process. Experimental evidence pointed out that while ADAMTS-4 can 
be up-regulated by IL-1b, TNF-a and TGF-b (Arai, Anderson et al. 2004, Song, 
Tortorella et al. 2007, Rogerson, Chung et al. 2010), ADAMTS5 mRNA levels 
seam quite stable and independent from cytokines.  Another interesting point is 
that ADAMTS4 expression seams to be quite ubiquitous among all tissues, while 
ADAMTS5 is restricted to few tissues. Vankemmelbeke and colleagues have 
shown that active ADAMTS-5 is expressed in osteoarthritic human synovium, 
suggesting that this tissue could contribute to articular cartilage destruction 
(Vankemmelbeke, Holen et al. 2001). In vitro studies also evidenced that 
ADAMTS-5 is almost a thousand time more active than ADAMTS-4 (Gendron, 
Kashiwagi et al. 2007). Based on these experimental evidences it is still debating 
if cytokine blocking agents may be a useful tool to alt aggrecan loss derived from 
aggrecanases-dependent activity. Current studies however suggest that inhibition 
of both ADAMTS-4 and ADAMTS-5 may be required to achieve maximum drug 
efficacy in treating OA Moreover some researchers speculated that ADAMTS 
inhibitors that block the progression of OA might be more successful than 
inhibitors that block the initial stages (Cooper, Snow et al. 2000). This is because 
many patients with early stage OA remain stable for long periods of time and 
some do not progress at all (Hunter and Felson 2006, Smelter and Hochberg 
2013). Recently, AGG-523, an ADAMTS-4/-5 inhibitor developed by Wyeth, 
was shown to reduce the release of aggrecanase-generated aggrecan fragments 
into rat joints and has advanced to Phase I clinical trials for the treatment of OA 
(Chockalingam, Sun et al. 2011). 
1.3.4 Tissue inhibitors of metalloproteinases 
Four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) molecules are present in 
vertebrates and their expression is regulated during development and tissue 
remodelling (Brew and Nagase 2010). All mammalian TIMPs have two distinct 
domains, a N-terminal domain of about 125 amino acid residues and a C-terminal 
domain with about 65 residues; the conformation of each domain is stabilized by 
three disulphide bonds (Williamson, Marston et al. 1990). The four human 
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TIMPs share about 40% of identity in sequence to each other. The mechanism by 
which TIMPs inhibit metalloproteinases was suggested by Gomis-Rüth and 
colleagues (Gomis-Ruth, Maskos et al. 1997).  In this mechanism two pair of four 
residues in the N-terminal domain of the inhibitor, linked by a disulphide bond, 
slots into the active site of the enzyme, chelating the zinc atom, and expelling the 
water in the pocket.  Recombinant forms of the N-terminal domains of TIMPs, 
designated N-TIMPs, have stable native structures and are fully active as 
inhibitors of MMPs and some ADAMTSs (Murphy, Houbrechts et al. 1991, 
Kashiwagi, Tortorella et al. 2001). 
The four human TIMPs are broad-spectrum inhibitors of the 23 MMPs found in 
humans, but there are some differences in specificity among them. TIMP-1 for 
example is more restricted in its inhibitory range than the other three TIMPs, 
having a relatively low affinity for the membrane-type MMPs. Besides TIMP-3 
by far has the broadest activity among all TIMPs; in addition to all the MMPs it 
inhibits also several ADAMs (ADAM-17 and ADAM-10) as well as 
aggrecanases (ADAMTS-4 and ADAMTS-5) (Amour, Slocombe et al. 1998, 
Amour, Knight et al. 2000, Kashiwagi, Tortorella et al. 2001). Kinetic studies 
indicates that TIMP-3 is a better inhibitor for ADAM-17 and aggrecanases than 
for MMPs. ADAM-17, also known as TACE (tumor necrosis factor-α converting 
enzyme) catalyses the release of soluble TNF-α from its membrane-bound 
precursor, which was shown to be able to increase ADAMTS-4 expression. 
Being able to inhibit both ADAM-17 and aggrecanases, TIMP-3 plays an 
important role in regulating inflammatory processes, and targeting this molecule 
may lead to affect the progression of pathological processes such as cancer, 
rheumatoid arthritis and osteoarthritis (Murphy and Nagase 2008, Rocks, 
Paulissen et al. 2008). While TIMP-2 and TIMP-4 do not contain carbohydrates, 
TIMP-1 and TIMP-3 are glycoproteins; as result TIMP-3 binds tightly to the 
sulphated glycosaminoglycans of the ECM (Yu, Yu et al. 2000). This feature 
both affects the protein behaviour but also makes it very difficult to handle in 
vitro, and particularly to purify or extract it from cartilaginous tissue. Although 
human and mouse TIMPs share an elevated identity is structure, they present a 
different glycosylation pattern. 
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TIMPs are natural inhibitors of MMPs, ADAMs and ADAMTSs, that have been 
linked to multifarious diseases in humans including cancer, rheumatoid arthritis, 
osteoarthritis, heart and kidney diseases, thus they are attractive target for	
potential clinical applications. An approach to the therapy of metalloproteinase-
related diseases is the use of engineered TIMPs with restricted inhibitory 
specificities. 
1.3.5 TIMP-3 
Because of its broad inhibitory spectrum has been extensively studied and it has 
been indicates as the major regulator of metalloproteinase in vivo. Timp3 null 
mice, generated by Khokha and colleagues, have been shown to suffer of air 
space enlargement in lungs (Gill, Pape et al. 2003) and enhanced apoptosis of 
mammary epithelial cells after weaning (Fata, Leco et al. 2001), compared to 
Timp1 null mice and Timp2 null mice, which do not exhibit obvious 
abnormalities unless those animals are challenged. Timp3 null mice also suffer of 
chronic hepatic inflammation and are affected by impaired liver regeneration 
(Mohammed, Smookler et al. 2004), cardiomyopathy and abnormal 
vascularization with dilated capillaries (Fedak, Smookler et al. 2004, Janssen, 
Hoellenriegel et al. 2008). Sahebjam and colleagues have shown that mice 
lacking Timp3 gene suffer of abnormal collagen and aggrecan degradation that 
increase with aging (Sahebjam, Khokha et al. 2007). Mutations in the TIMP3 
gene in human are associated with Sorsby’s fundus dystrophy, an autosomal-
dominant disease that causes blindness due to macular degeneration. Mutated 
TIMP-3 seams to acquire enhanced stability in the extracellular space, affecting 
the turnover of the surrounding matrix (Majid, Smith et al. 2007). Interestingly 
all the mutations are found in the C-terminal domain producing either a single 
amino-acid substitution or a nonsense mutation (Qi, Ebrahem et al. 2003).  
1.3.5.1 TIMP-3 as potential target in human diseases 
Application of TIMPs as a therapeutic tool for gene therapy or direct protein 
application is a promising but still not fully developed approach (Baker, Edwards 
et al. 2002). However, there is a clear potential for the application of TIMPs as 
endogenous inhibitors, especially because the results of clinical trials with small 
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molecule inhibitors failed to provide appreciable results. However, expressing 
wild-type TIMPs could have drawbacks because multiple MMPs may be 
inhibited, and in the case of TIMP-3, ADAMs and ADAMTSs may be inhibited 
as well. A promising route to success is the development of engineered TIMPs 
with altered specificity, to allow targeting of specific proteinases. To date one of 
the best results was achieved by Wei and colleagues adding an extra alanine 
residue to the N-terminus of TIMP-3 (Wei, Kashiwagi et al. 2005). The synthetic 
mutant so generated ([-1Ala]N-TIMP-3) was shown to retain ability to inhibit 
ADAM-17, but it impaired the inhibition of MMPs. Further studies by Lim and 
colleagues demonstrated that this synthetic mutant was still able to block 
ADAMTS-4 and -5 in vitro (Lim, Kashiwagi et al. 2010). 
1.4 Osteoarthritis 
1.4.1 Overview 
OA is the most common joint disease (arthropathy) and is characterized by joint 
pain and loss of joint function (Hunter and Felson 2006). Although it was 
previously described as a non-inflammatory arthritis, the use of new diagnostic 
technique as MRI, led to understand that inflammation is very common within 
the OA joint. In particular inflammation of the synovial lining of the joint 
(synovitis) is almost ubiquitous in knees affected by OA (Conaghan, Felson et al. 
2006)  
Evolution of OA leads to loss of articular cartilage, subchondral bone thickening 
and new bone formation in a synovial joint. Osteoarthritis affects approximately 
15% of the total population and greater than 50% of the population over 60 years 
of age (Poole, Kobayashi et al. 2002). OA represents an enormous socio-
economic challenge, with millions of people affected worldwide. The aging of 
the population, coupled with epidemic increases in other risk factors such as 
obesity, suggests that the impact on society of OA-related problems will continue 
to rise (Lawrence, Felson et al. 2008). Severities of pain and loss of cartilage are 
highly variable among patients, affecting the therapeutical approach. To date 
drug therapy options are currently limited to palliative treatment with analgesics 
and NSAIDs (Non-steroidal anti-inflammatory drugs) (Berenbaum 2008). Such 
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treatment usually lasts until loss of function of the joint, when the only option is 
partial or total prosthetic replacement. 
 
 
Figure 1.5. Osteoarthritic changes in the anterior of the right knee. OA progression results in 
erosion of cartilage and exposure of the underlying bone 
(http://www.christchurchosteopathy.co.uk/018.html). 
1.4.2 Clinical aspects of osteoarthritis 
Because cartilage lacks neural connections, symptoms of OA often do not present 
until late stage disease. Osteoarthritis can be subdivided as either idiopathic (of 
an unknown cause) or secondary (caused by another disease or condition). 
Physical symptoms upon examination of osteoarthritic joints include: pain, 
decreased range of motion, effusions and tenderness on palpation. Patients may 
describe localised pain on exercise (which is relieved by rest) and stiffness during 
periods of inactivity. 
The diagnosis of OA revealed to be a quite difficult task and many efforts are 
made towards the prediction of OA. To date diagnosis is currently based on 
radiographic criteria (e.g., joint space width) and clinical symptoms (e.g. pain and 
loss of function). However, the limitations of radiography (e.g. technical issues, 
precision and sensitivity) (Hunter and Guermazi 2012) have led to research into 
other biomarkers for monitoring osteoarthritis. Imaging markers such magnetic 
resonance may be useful tools in the evaluation of OA and in drug development 
in the field (Eckstein, Le Graverand et al. 2011, Eckstein and Wirth 2011).  
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A promising outcome is the use of quantitative magnetic resonance imaging 
(MRI) of the joint structure to detect minute changes in cartilage structure, and 
thus predict the joint pathogenesis (Hunter, Li et al. 2007, Dam, Loog et al. 2009, 
Binks, Hodgson et al. 2013). Molecular changes are obviously difficult to detect, 
because cartilage undergoes continuous remodelling, a process that can hide 
pathological changes. However, widespread use of MRI is limited by cost, 
availability and the absence of a validated international score. Another attractive 
alternative is the measurement of biochemical markers in blood, urine or synovial 
fluid samples, which could reflect the metabolic changes of the joint and 
therefore hint to disease progression. To date the biomarkers with the most 
consistent evidence appear to be those at the end of the pathways of tissue 
destruction. Belong to this group the C-terminal telopeptide of collagen type II 
(CTX-II) and Cartilage oligomeric matrix proteins (COMPs) (Posey and Hecht 
2008, Sowers, Karvonen-Gutierrez et al. 2009). Pharmacological therapy for 
osteoarthritis relies on pain relief-drugs such as paracetamol, non-steroidal anti-
inflammatory drugs (NSAIDs), cyclooxygenase 2 (COX-2) inhibitors and 
opioids. Surgical intervention for joint replacement is used in advanced stages of 
OA (Conaghan, Dickson et al. 2008). There are no currently available disease-
modifying osteoarthritis drugs. Trials to regulate endogenous catabolic factors by 
administering proteinases inhibitors against MMP-13 and ADAMTS-5 targets 
have been unsuccessful because of insufficient efficiency and adverse events 
(Little, Meeker et al. 2007, Fosang and Little 2008, Troeberg, Fushimi et al. 
2008, Flannery 2010). 
1.4.3 Aetiology of osteoarthritis 
Aetiology of Osteoarthritis is still a controversial topic. The variability of patients 
and progression of the condition cannot be explained with a single model, and 
thus should be addressed as a multifactorial pathological condition.  
OA undoubtedly has a genetic element as has been demonstrated in sibling 
studies, familial aggregation and twin pair studies; however it is clear that occurs 
a complex interaction between genetic and environmental factors in OA 
aetiology, with susceptibility differing according to gender, age and quality of 
life. Susceptibility to OA appears to be influenced by a wide number of genetic 
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variations (as proved by several mouse transgenic or knockout models). 
Mutations in genes that encode for cytokines such as IL-1 and IL-6, and 
polymorphisms in cytokine and metalloproteinase genes are correlated to onset of 
OA. Mechanical stress, obesity, aging and gender are now generally accepted as 
risk factors associated to the development and progression of osteoarthritis 
(Buckwalter and Mankin 1998, Felson 2005). 
Some studies pointed toward a connection between high levels of physical 
activity and incident of knee OA. Anterior cruciate ligament (ACL) or meniscal 
tissue damage also results in increased risk of developing OA (Englund 2004, 
Sharma, Eckstein et al. 2008). However, a link between low-impact recreational 
exercise and OA is controversial. Obesity is a well-established risk factor for OA 
(Sowers and Karvonen-Gutierrez 2010). In line with the upward trend in mean 
population Body mass index (BMI), the prevalence of OA is also increasing. 
Longitudinal data indicate that two in three obese adults will develop 
symptomatic OA in their lifetime (Murphy, Schwartz et al. 2008). The 
mechanisms for how obesity influences OA are unclear and a possibility is that 
increased body mass, increases mechanical stress placed on joints (Wluka, 
Lombard et al. 2013). However it is known that adipose tissue produces 
adipokines (such as leptin) as well as inflammatory cytokines. Leptin is found in 
synovial fluid, chondrocytes and osteophytes in osteoarthritic knees, with levels 
related to those of insulin-like growth factor-1 (IGF-1) and transforming growth 
factor-β (TGF-β) (Dumond, Presle et al. 2003). In the leptin-impaired mouse 
model of OA, obesity did not increase the prevalence of OA (Griffin, Huebner et 
al. 2009). It has been reported that knee-injection of leptin up-regulates 
expression of some collagenases and aggrecanases, and is associated with 
depletion of proteoglycan in rat  (Bao, Chen et al. 2010). In summary, excessive 
wear and tear through joint overuse, obesity, joint instability and finally gross 
damage to the articular cartilage surface are all strongly associated with the 
development of OA. 
It is now well accepted that aging is correlated to OA onset (Loeser 2013). OA is 
rare in adults under 40 and prevalence rates of radiographic OA rise steeply after 
the age of 50 in men and age 40 in women (Felson, Zhang et al. 1995). Gender is 
also a well-recognised risk factor in OA. Evidences suggest an association 
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between endogenous oestrogen and cartilage turnover and radiographic OA, and 
between testosterone and cartilage volume. There is also evidence for an 
association between exogenous oestrogen and cartilage and bone turnover 
(Tanamas, Wijethilake et al. 2011). These data suggest oestrogen have a chondro-
protective role against OA. A study of cartilage volume in postmenopausal 
women reported use of long-term oestrogen replacement therapy (ERT) had 
significantly greater cartilage volume than controls and ERT may prevent knee 
articular cartilage degradation (Wluka, Davis et al. 2001). 
1.4.4 GWAS studies on OA 
As previously mentioned osteoarthritis is referred as a complex disease and as 
such has to be investigated. OA is a set of disorders of the musculoskeletal 
system characterized by degradation and loss of articular cartilage in synovial 
joints. OA development appears to be a result of a complex set of interactions 
between mechanical, biological, biochemical, and molecular factors that 
destabilize the normal coupling of degradation and synthesis of articular cartilage 
chondrocytes and extracellular matrix, and subchondral bone. A substantial 
genetic component for OA has been demonstrated by studies on twin pair, sibling 
and families. Those studies highlighted that OA is transmitted in a non-
Mendelian manner, which is typical of multifactorial diseases. 
In the last decade we assisted to a revolution on the investigation of large 
genomes enabled by the advent of Next generation sequencing (NGS) techniques 
(Behjati and Tarpey 2013).  
This has enabled identification and tagging of single nucleotide polymorphisms 
(SNPs), non-redundant markers responsible of the majority of common variations 
across the genome, which led to the development of high throughput genotyping 
platforms in which hundreds of thousands of SNPs can be concurrently examined 
for association with pathologies. This new approach was successfully applied to 
several common complex diseases and traits.14, leading to the identification of 
numerous novel associations between genomic variation and disease. OA was 
relatively late to enter the genome-wide association scans (GWAS) era but 
recently a very broad study performed by the arcOGEN consortium successful 
led to the discovery of five loci with genome-wide significant association and of 
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three near this level (Apte, Hayashi et al. 1994). They identified five genome-
wide significant loci for association with osteoarthritis and three loci just below 
this threshold. The most significant signal was on chromosome 3 where two 
SNPs were found in perfect linkage disequilibrium (LD) with each other: 
rs11177, a missense polymorphism within exon three of GNL3 and rs6976 
situated in the 3ʹ untranslated region (UTR) of the GLT8D1 gene. These SNPs 
were found consistent in both OA types investigated (knee and hip). The 
potential role of those two genes in OA is however still unknown. Interestingly 
another SNP identified was the rs8044769. This SNP was found associated with 
OA in females. It is located within intron 1 of FTO (fat mass and obesity 
associated) gene. Variation in the FTO gene is known to play an important role in 
susceptibility to obesity (Fawcett and Barroso 2010) and overweight/obesity is a 
well established risk factor for OA susceptibility and it is also a predictor for OA 
progression, especially of the knee joint (Lohmander, Gerhardsson de Verdier et 
al. 2009). An earlier study conducted by Miyamoto and colleagues on Japan 
population identified the allelic variation rs143383 affecting the GDF5 gene in 
hip OA patients (Miyamoto, Mabuchi et al. 2007). Gdf5 was shown to have 
multiple functions in mouse skeletogenesis, including roles in joint and cartilage 
development (Storm and Kingsley 1999).  
1.4.5 Cartilage modifications in the OA pathogenesis 
Macroscopically, OA cartilage is often yellowish, compared to the whitish of the 
normal cartilage, typically soft and swollen. Histological changes of osteoarthritis 
are well characterised. Initially there is an progressive loss of proteoglycan, the 
articular cartilage surface loses its smooth appearance, and fibrillation starts to 
appear (Meachim, Ghadially et al. 1965). As disease progress fissures opens in 
the cartilage starting from the middle zone and advancing inward towards the 
calcified cartilage (McElligott and Collins 1960).  Safranin-O staining of 
cartilage proteoglycans would show a decrease of red colour until complete white 
staining, matching the complete loss of proteoglycans. Chondrocytes behaviour is 
peculiar because cells are seen to form clusters and proliferate, as an attempt to 
regenerate the tissue (Meachim, Ghadially et al. 1965, Meachim and Sheffield 
1969). However a progressive cell death is observed, via apoptosis, which leads 
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to a hypocellularity of the tissue. Cartilage is now lost, subchondral bone is 
exposed and the whole joint in no functional anymore. The grading system most 
commonly used (partly with minor modifications) is the histochemical-histologic 
grading system designed by Mankin and co-workers in 1971 (Mankin, Dorfman 
et al. 1971). 
1.4.6 ECM modifications in the OA pathogenesis 
The destruction of articular cartilage and the loss of its biomechanical function 
are largely due to the destruction and loss of the territorial cartilage matrix. Our 
knowledge focuses on degradation processes of the two major components of the 
interterritorial ECM, the collagen network and the interwoven proteoglycan 
aggregates. Loss of aggrecan and its negative charges is characteristic of the early 
stages of cartilage degeneration, whereas the overall content of collagen remains 
rather constant nearly throughout the disease process. Still, loosening of the 
collagen network is a major feature also in early cartilage degeneration. So far, it 
is unknown what happens first if the loss of proteoglycans or the loosening of the 
collagen network, because each one eventually influences the other as well. 
Loosening of the collagen network leads to a loss of proteoglycans, and a loss of 
proteoglycans leads to a mechanical overload and, thus, damage and loosening of 
the collagen network. In particular, the latter appears to be responsible for the 
hyperhydration of articular cartilage in the early phases of the disease process, 
macroscopically visible as softening and swelling of the OA articular cartilage. 
Degradation processes appear to be specifically prominent in the surface zone 
and around the chondrocytes in OA cartilage. It has been suggested that the 
earliest events in OA is the loss of aggrecan core protein from the cartilage ECM, 
and only after this happens the proteolysis of collagen fibres. However 
chondrocytes continuously synthesise aggrecan, turning the first event more 
difficult or rather reversible. Loss of collagens however is considered permanent 
because, despite repair attempts, the original fibrous collagen network cannot be 
restored (Karsdal, Madsen et al. 2008). Some study suggested that although 
broken, proteoglycan fragment could still be maintained in the place by the 
collagen structure, and thus maintaining the physiological property of the 
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cartilage. Only when collagens are lost these molecules can me washed away and 
impair the cartilage physiology.  
In OA, it is believed that there is an increase in matrix degradation through 
increased production of proteinases (ADAMTSs, MMPs), increased proteinases 
activity (increased cleavage of pro-enzymes) or decreased activity of catabolic 
regulators, TIMPs. According to this prospective, researches focused on mRNA 
levels of catabolic enzymes in human cartilage samples from late-stage OA 
donors has shown an increased expression of MMP1, MMP2, MMP9, MMP13, 
ADAMTS4 and ADAMTS5 in late stage OA cartilage (Bau, Gebhard et al. 2002, 
Aigner, Zien et al. 2003). 
It has been shown that aggrecan neoepitope, produced by both MMPs and 
ADAMTSs activity, are found in culture media of cartilage explants in vitro as 
well as human synovial fluid in vivo suggesting elevated aggrecanase/MMP 
levels of activity (Fosang, Last et al. 1996, Lark, Bayne et al. 1997, Sandy and 
Verscharen 2001, Little, Hughes et al. 2002). Little and colleagues, in a quite 
elegant study, generated an aggrecan knock-in mouse with a mutation between 
the G1 and G2 domains obtaining aggrecan molecule resistant to aggrecanase 
activity. This knock-in mutation significantly inhibited proteoglycan loss, 
diminished cartilage degradation and promoted cartilage repair (Little, Meeker et 
al. 2007). Adamts5 knockout mice are significantly resistant to IL-1α and retinoic 
acid induced aggrecan cleavage as well as surgically induced cartilage 
destruction, compared with wild-type mice (Glasson, Askew et al. 2005). 
However no protection towards OA was observed in Adamts4 knockout mice 
after surgical-induced OA. Because this evidences Adamts5 is believed to be the 
most important aggrecanase in mouse cartilage (Glasson, Askew et al. 2004). 
Interestingly Song and colleagues demonstrated that the depletion of either 
ADAMTS5 or ADAMTS4 using siRNA in human cartilage explants inhibits 
proteoglycan release when explants were stimulated with tumor necrosis factor-α 
(TNFα) and oncostatin M (OSM). This suggests that despite the dominant role of 
both ADAMTS-4 and ADAMTS-5 may contribute towards cartilage destruction 
in human osteoarthritis (Song, Tortorella et al. 2007). It has been recently shown 
that MicroRNA-125b regulates the expression of ADAMTS4 in human 
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osteoarthritic chondrocytes, making this MicroRNA a possible therapeutic target 
for OA (Matsukawa, Sakai et al. 2013).  
It has been shown in mice and in human cartilage explants that pharmacological 
or genetic inhibition of HH signalling reduces the severity of OA and that runt-
related transcription factor-2 (RUNX-2) potentially mediates this process by 
regulating ADAMTS5 expression. These findings raise the possibility that HH 
blockade can be used as a therapeutic approach to inhibit articular cartilage 
degeneration (Lin, Seeto et al. 2009). Moreover increased expression of RUNX2 
in OA cartilage may contribute to increased expression of MMP-13 (Wang, 
Manner et al. 2004). 
MMP-13 is thought to play a critical role in cartilage destruction being more 
active against type II collagen than other collagenases and chondrocyte 
expression of MMP13 mRNA is increased in late-stage human OA cartilage in 
association with cartilage erosion (Aigner, Zien et al. 2001). Constitutively 
overexpression of active human MMP13 in hyaline cartilage of transgenic mice 
resulted in OA-like cartilage modification at load bearing sites, similar to human 
OA including proteoglycan and type II collagen degradation (Neuhold, Killar et 
al. 2001). Little and colleagues demonstrated that the cartilage of Mmp13-/- mice 
is protected from structural cartilage damage in a surgically induced model of 
OA, however there was no significant reduction in aggrecanolysis, osteophyte 
development or chondrocyte hypertrophy (Little, Barai et al. 2009). Mmp13-/- 
mice were able to inhibit cartilage degradation in the presence of aggrecan loss; 
this may suggest that aggrecan depletion on its own does not drive cartilage 
degradation.  
1.4.7 Mouse models of osteoarthritis 
One of the reasons of the lack of knowledge in the osteoarthritis pathology is that 
sample tissues from patients are usually collected late in the disease process, 
when most of the cartilage tissue is already destroyed. A second reason is that 
OA is a slow progressive disease, and it may take years before a positive 
diagnosis. These evidences explain the major difficult to decide which animal 
model better represent the OA pathology. As a matter of fact, experimental 
animal will develop spontaneously OA-like cartilage erosion if left aging until 
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elderly. However this may take years, making it incompatible with research 
timeframe. For this reason were developed system that could induce 
osteoarthritic phenotype in experimental animals, in shorter period of time. 
Notably researchers identified in the STR/ort mice a model of spontaneous OA, 
where characteristic cartilage lesions are evident by 6 months of age (Mason, 
Chambers et al. 2001). This model although resembling the observed variability 
of the human disease is poor characterized at the molecular level, resulting in a 
too complex system. Some insight however suggested an important role in 
cartilage destructions played by reactive oxygen species (ROS) (Regan, Flannelly 
et al. 2005). An alternative arose with the development of surgical-induced OA 
models. These models can be applied in a variety of different animals: rats, dogs 
and mice (Kamekura, Hoshi et al. 2005, Bove, Laemont et al. 2006). However is 
the elective species for this kind of studies because relative lower cost of colonies 
maintaining, and because mouse is the primary species for the generation of 
transgenic animals, both knock-out and over-expressing. Glasson and colleagues 
demonstrated that severity of surgical-induced OA lesions and rate of the 
destruction progression can be affected by the type of surgery. For example 
anterior cruciate ligament transection (ACLT) produced a much more severe OA 
phenotype compared to the destabilization of the medial meniscus (DMM) 
surgery. In both system the destabilization of the joint structure, led to friction of 
the cartilage surface, and progressive erosion of the tissue. The DMM model was 
shown to provide extremely good reproducibility and a slower progression of 
disease, resembling more the human OA, and thus was elected as method of 
choice for many studies. Most of the damage in DMM model is concentrated in 
the medial tibia plateau and femoral condyles, while the laterals are relatively un-
affected. Cartilage damage in evaluated according to the OARSI (Osteoarthritis 
Research Society International) Histopathology Initiative system that has been 
recently published (Glasson, Chambers et al. 2010). Most importantly Glasson 
and colleagues demonstrated that after DMM surgery male mice develop a more 
severe OA than females, but also ovariectomized female are more protected 
against OA compared to intact females. These findings suggest that hormones 
play a critical role in the progression of OA in the murine DMM surgical model 
(Ma, Blanchet et al. 2007). It has been observed that if joints are immobilized by 
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sciatic neurectomy, after DMM surgery, the regulation of selected genes, 
including	Adamts4 and Adamts5, was abrogated and OA was prevented up to 12 
weeks post surgery (Burleigh, Chanalaris et al. 2012). However a disadvantage of 
the surgical models is that only knee damage can be studied. Osteoarthritis can 
been induced in laboratory animals also by intra-articular injection of modifying 
substances such as collagenase, that some authors describe as more resembling 
the human disease compared to surgically induced instability. Knee injection of 
mono-iodoacetate, to alter chondrocyte metabolism, is another method that 
produces OA-like morphological changes in mice knees (Guingamp, Gegout-
Pottie et al. 1997, Bove, Calcaterra et al. 2003). Finally Poulet and colleagues 
have recently characterised a non-surgical model for controlled mechanical 
loading of murine knees that may help to identify the contribution made by 
precise mechanical factors to OA (Poulet, Hamilton et al. 2011). In this model 
peaks loads of 9N are applied through natural points of articulation, with the 
contralateral joint experiencing normal gait between loading episodes, providing 
an internal control. An evident advantage of this model is the non-invasiveness 
that reduces the risk of infections, and thus of an immune response affecting the 
articular cartilage itself. 
1.5 Transgenic mice 
1.5.1 Overview 
Transgenic animals for research are extensively used to study in vivo gene 
function as well as to model human diseases. The technology for producing 
transgenic animals exists for a variety of vertebrate and invertebrate species such 
as: pig, rabbit, rat mouse, zebra fish, drosophila and nematode. Choosing the best 
animal model usually rely on previously published literature as well as the level 
of complexity that can be afforded. Research on epigenetic and molecular 
biology mechanism is often carried out in drosophila, which require minimum 
colony space, relatively easy handling and has short time of reproduction. Mice 
are often employed for drug delivery studies, as well as model of human genetic 
diseases, but require relatively higher cost in colony maintaining and handling.  
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The most commonly used techniques for producing transgenic mice involves 
either the pronuclear injection of transgenes into fertilized oocytes or embryonic 
stem cell-mediated gene targeting. Embryonic stem cell technology has been 
most often used to produce null mutants (knock-outs) but may also be used to 
introduce exotic genes (knock-ins) or modifications down to the level of making 
single nucleotide changes in endogenous mouse genes. Methods are also 
available for inducing conditional gene knockouts as well as inducible control of 
transgene expression. Working with transgenic and knockout mice can be 
challenging and is often hampered by limitations and technical problems. The 
most common limitations involved construction of the transgene, generation and 
characterization of founder lines, and maintenance of a transgenic colony. 
1.5.2 Cre/loxP system 
The most common method to alter gene expression in a conditional manner is the 
use of the Cre/loxP system. Cre is an enzyme found in the P1 bacteriophage that 
acts as a site-specific recombinase; it recognizing a short sequence of DNA called 
a loxP site. A loxP site is a consensus 34-bp DNA sequence that is not present in 
the mouse genome and has directionality. Cre-mediated recombination of genes 
flanked by loxP sites (also called a floxed sequence) can result in the excision, 
inversion, or translocation of DNA depending upon the location and orientation 
of the loxP sites. The most common use of Cre recombinase is to excise or delete 
a floxed DNA sequence (Nagy 2000). Cre-mediated recombination has been 
shown to occur in a variety of cell types (Sauer 1998, Feltri, D'Antonio et al. 
1999) and that only a few Cre molecules per cell are needed to excise the floxed 
DNA. Cre recombinase mediates a permanent deletion of the floxed DNA, and if 
cell division occurs after Cre-mediated recombination, all daughter cells will 
inherit this gene deletion. 
To allow for cell type-specific control of gene deletions, mouse models have 
been created where Cre expression is controlled by a cell type-specific promoter. 
Crossing them with mouse lines containing a relevant part of a target gene 
enclosed in loxP sites allows obtaining cell-type specific deletion. Cre-loxP 
system can be employed to induce the overexpression or ectopic expression of a 
target gene. In this case, a construct containing a promoter and a floxed “stop” 
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sequence upstream of target gene or coding sequence, is inserted into the 
genome; thus, only Cre-positive cells are able to remove the “stop” sequence and 
overexpress or ectopically express the gene (Gao, Wu et al. 2004). 
To gain temporal control of gene expression, the ligand-binding domain of an 
engineered oestrogen receptor is fused to the Cre enzyme and the Cre molecules 
are sequestered in the cytoplasm by heat shock protein 90 (Hsp90), keeping Cre 
inactive. The translocation of the Cre/oestrogen receptor fusion protein to the 
nucleus, which allows Cre to become active, only occurs in a ligand-dependent 
manner, thus inducible (Feil, Brocard et al. 1996, Hayashi and McMahon 2002). 
Improvement to prevent Cre activation by endogenous steroid hormones, leads to 
introducing specific point mutations that make it insensitive to endogenous 
oestrogen while retaining binding affinity for synthetic analogues such 
tamoxifen. 
1.5.3 Cartilage specific expression 
Many attempts had been made to obtain chondrocytes specific expression both in 
vitro and most importantly in vivo.  
The study of chondrocytes gene expression in mouse led to identifying several 
promoters to target this cell type. Such targeted promoters span from 
transcription factors implicated in early commitment or maintenance of 
chondrocyte phenotype, as well as genes responsible for structural maintenance 
of articular cartilage. The former ones include Prx1-Cre (Logan, Martin et al. 
2002), Dermo-Cre (Yu, Xu et al. 2003), Gdf5-Cre (Rountree, Schoor et al. 2004) 
, Sox9-Cre (Akiyama, Kim et al. 2005); to the second group belong the Col10a1-
Cre (Gebhard, Hattori et al. 2008), and Col11a2-Cre (Fujimaki, Hayashi et al. 
2005) . 
One important notion is that chondrocytes in adult mice could be found at 
different differentiation stages, so the choice of promoter can determine whether 
the expression be restricted to a specific subset of cells. Collagen type II and type 
X promoters were mostly used in studies aimed to proliferative and hypertrophic 
chondrocytes respectively. More recently the use of Aggrecan promoter/enhancer 
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has been exploited and revealed itself as the best system to target non-
hypertrophic, mature chondrocytes. 
Collagen type II is an early marker for chondrogenesis and is expressed from 
embryonic day E9.5 in mouse in mesenchyme destined to develop in sclerotome 
of the somites. The collagen type II gene (Col2a1) is expressed in all 
chondrogenic tissues of the axial and appendicular skeleton until onset of 
endochondral ossification. However, it is also expressed transiently at low levels 
in certain non- chondrogenic tissues, including notochord, eye, heart, epidermis 
and discrete areas of the brain (Cheah, Lau et al. 1991). First Zhou and 
colleagues in 1995 investigated chondrocyte specificity of the Col2a1 promoter 
in murine embryos (Zhou, Garofalo et al. 1995). They initially identified a large 6 
kb sequence, spanning from putative promoter regione to exon 1, which was able 
to drive β-galactosidase expression in chondrocytes. Following deletion studies 
revealed that a 182 bp fragment within intron 1 was sufficient to target 
expression in chondrocytes even using a different promoter, although it showed 
additional expression in the brain (Leung, Ng et al. 1998). Lefebvre and 
colleagues in 2008 shown that four copies of a 48 bp intron 1 fragment were 
enough to drive strong expression in chondrocytes, when linked to a 309 bp 
Col2a1 promoter sequence. Their system also drove cartilage specific expression 
in vivo. To date the most used cartilage specific Cre-exprtessing line is the one 
generated by Ovchinnikov and colleagues (Ovchinnikov, Deng et al. 2000). They 
used a 3 kb sequence of the Col2a1 promoter region and 3.02 kb fragment of 
intron 1, obtain Cre-recombianse expression early during cartilage development 
and later in the adult cartilage, hover some expiression was observed in 
notochord and cranial mesenchyme as well. A similar mouse line generated by 
Belteki and colleagues showed high cre recombinase levels in epidermis eye and 
heart (Belteki, Haigh et al. 2005). In contrast to the vast amount of knowledge on 
the regulation of Col2a1 promoter, Aggrecan regulation has been far less 
researched. Doege and colleagues studied the Aggrecan promoter regulation in 
vivo. They identified cell-specific enhancer elements in a 4.7 kb DNA fragment 
12 kb upstream of the transcription start site that strongly stimulated Aggrecan 
expression in chondrocytes (Doege, Hall et al. 2002). Han and Lefebvre 
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identified in the same 4.7 kb region a highly conserved region directing 
specificity of Aggrecan expression in embryonic and adult cartilage (Han and 
Lefebvre 2008). This region drove expression differently as Col2a1 reporters, in 
fact it was not expressed in skeletogenic mesenchymal cells, perichondrium and 
presumptive joint cells, but was strictly specific for differentiated chondrocytes. 
Moreover, it remained active through adulthood whereas Col2a1 was less active 
upon ageing. This would make this Aggrecan enhancer region an interesting tool 
for expressing transgenes in differentiated chondrocytes in adulthood. Finally in 
2009 Henry and colleagues generated a tamoxifen inducible cre recombinase-
expressing mouse, cloning in the enzyme coding sequence downstream the 3' 
untranslated region of the endogenous mouse Aggrecan gene (Henry, Jang et al. 
2009). Aggrecan gene has been shown to be expressed also in other mouse 
tissues such brain (Domowicz, Sanders et al. 2008). 
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AIMS 
1.a. To design and generate an expression vector driving cartilage specific 
expression. I will use the sequence identified by Han and Lefebvre (Han and 
Lefebvre 2008) to generate a vector that drives robust expression of both 
CreERT2 recombinase and Luciferase in chondrocytes. 
1.b. To generate transgenic mice as a tool for cartilage specific Cre-mediate 
recombination in vivo. I will use an expression vector driven from the Aggrecan 
enhancer elements to generate a Cre-deleter. 
Hypothesis: The aggrecan enhancer elements are sufficient to drive the 
expression in chondrocytes. Being the chondrocytes the sole resident cell into 
cartilage, transgenic expression will be restricted to this tissue only. The 
transgenic mice line generated will serve as a unique tool to study cartilage 
development and/or pathologies.  
2.a. To generate transgenic mice lines to overexpress TIMPs protein in mouse 
cartilage. I will use the same Aggrecan enhancer sequences identified before. 
Hypothesis: Osteoarthritis is a multifactorial disease affecting a increasing 
number of people worldwide. Articular cartilage destruction is the key event of 
this pathology and a predominant role of enzymes that affect the homeostasis of 
the cartilage protein component is generally accepted. Because most of those 
enzymes are regulated by TIMPs, I want to overexpress these inhibitors in 
cartilage to evaluate potential beneficial activities.  
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Chapter 2  
Materials and Methods 
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2.1 Materials 
2.1.1 General Reagents 
Unless otherwise stated, all chemicals were supplied by Sigma-Aldrich (Dorset, 
UK) or BDH Chemicals (Dorset, UK) and are of the highest quality. Bovine 
serum albumin, electrophoresis grade (BSA) was from PAA Laboratories 
(Pasching, Austria). Phosphate buffered saline (PBS) was obtained as a 10x 
sterile solution (VWR, Lutterworth, UK). A 1xPBS solution was generated by 
diluting the 10x stock with ultrapure ddH2O. 
2.1.1.1 Cloning 
- DH10b Competent cells (Stratagene) 
- Luria-Bertani (LB) medium: (Invitrogen) 
- Agar (Invitrogen) 
- Agarose (Invitrogen) 
- 0.5kb DNA Ladder (New England BioLabs) 
- 1kb DNA Ladder (New England BioLabs) 
- QIAquick PCR purification kit (Qiagen) 
- QIAquick gel extraction kit (Qiagen) 
- QIAfilter plasmid maxi kit (Qiagen) 
- T4 DNA ligase (New England BioLabs) 
- T4 DNA Polymerase (New England BioLabs) 
- Polymerase I Large (Klenow) Fragment (New England BioLabs) 
- Alkaline phosphatase (CIP, calf intestinal, New England BioLabs) 
- Restriction enzymes (New England BioLabs) 
- Platinum Taq DNA Polymerase (Invitrogen) 
2.1.1.2 Cell culture 
· DMEM (4.5g/l) liquid with Sodium Pyruvate with L-Glutamine (PAA 
Laboratories) 
· FBS (PAA Laboratories) 
· Penicillin/streptomycin (PAA) 
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· Trypsin-EDTA (1x) 0.05% / 0.02% in DPBS (PAA Laboratories) 
2.1.1.3 RT-qPCR 
- High Capacity cDNA Reverse Transcription kit (Applied Biosystems) 
- TaqMan® Universal PCR Master Mix (Applied Biosystems) 
- ABI PRISM™ 384-Well Clear Optical Reaction Plate with Barcode (Applied 
Biosystems) 
- RNeasy Micro Kit (Qiagen) 
- DNase I (Qiagen) 
- QIAprep Spin Miniprep Kit (Qiagen) 
2.1.1.4 Immunofluorescence 
- Goat Serum (X0907, Dako) 
- antiTIMP-3 Rabbit polyclonal (AB6000, Millipore) 
- antiRabbit Goat polyclonal Alexa Fluor® 488 (A-11034, Life Technology) 
- DAPI 1:1000 (Sigma) 
- ProLong® Gold Antifade Reagent (Life Technology) 
2.1.1.5 Mouse transgenesis 
- Hypnoval (Roche) 
- Hypnorm (Janssen) 
- Chorulon (Intervet) 
- Folligon (Intervet) 
2.1.2 Restriction Enzymes 
All DNA constructs were digested using Neo England Biolab (NEB) enzymes or 
Fast Digest® (Fermentas) enzymes. NEB enzymes were allowed to digest the 
substrate for 4 hours with specific buffers according to the manufacturer 
specifications working temperature. Digestions employing the Fast Digest® 
enzymes were performed for 2 hours. All enzymatic digestions were performed 
in water bath, and using a total volume of 20 µl. 
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2.1.3 Principal instruments and software 
Samples were visualized on an Olympus SZX12 dissecting stereomicroscope 
with illumination either from below or from a fibre optic light source. 
Microscope was equipped with 10x/0.40 and 20x/0.70; ∞/0.17 lenses (Olympus). 
Images were captured with a digital CCD camera (model QIClick-F-CLR-12) 
using accompanying software. The 7900HT Fast Real-Time PCR System real-
time thermal cycler and software were from Applied Biosystem. Gel Doc XR+ 
system and Quantity One® software were from Bio-Rad Laboratories. Graphs 
and statistical analysis were performed using GraphPad Prism 6.0. Neon 
Transfection system and all buffers related were from Life Technology. Confocal 
images were acquired using the Ultraview confocal microscope (PerkinElmer 
Life Sciences) with a 60x objective lens and equipped with a Nikon TE-2000 
digital CCD camera.  
2.2 Methods 
2.2.1 Standard manipulation of DNA 
2.2.1.1  Agarose gel electrophoresis 
Digestion products were separated by agarose gel electrophoresis. UltraPure 
Agarose from Invitrogen was used and percentage was always 1% in Tris-
Acetate-EDTA (TAE) buffer, if not otherwise specified. TAE buffer was made as 
stock solution 50x and diluted to 1x as working solution. To visualize DNA 
fragment, Ethidium Bromide (EtBr) was added to the agarose solution to a final 
concentration of 0.3 µg/ml. Gel electrophoresis was performed using Bio-Rad 
Wide Mini-Sub Cell GT Systems setting the instrument to 55 V. As molecular 
weight marker 1kb DNA ladder was used. An UV light trans-illuminator set to 
365 nm wavelengths was used to visualize DNA fragment. Exposure was shortest 
as possible to avoid DNA damage. 
2.2.1.2  DNA recovery 
To recover fragments of interest, the corresponding portion of the agarose gel 
was cut using a sterile scalpel and transferred into a sterile 1.5 ml tube. DNA was 
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eluted using QIAquick Gel Extraction Kit according to manufacturer 
specification. Briefly, sample is dissolved into QG buffer at 50°C, than solution 
was spun down throughout a column that traps DNA. Column was washed using 
specific buffer and then DNA eluted in proper volume using Elution Buffer 
provided or Tris-EDTA buffer. 
2.2.1.3 Blunt-ending 
In case of blunt-end ligation as final step, digested constructs were treated with 
DNA Polymerase I Large (Klenow) Fragment, 15 min 37°C, than 20 min 65°C to 
inactivate the enzyme. 
2.2.1.4 De-phosphorylation 
Vectors were always de-phosphorylated using Calf Intestine Phosphatase (CIP) 
60 min at 37°C. 
2.2.1.5 Ligation 
Ligations were performed using 20 ng of vector fragment and the amount of 
insert fragment calculated adjusting for the molar weight; molar ratio 
insert/vector was usually 3:1. Ligations were performed into a total volume of 20 
µl using T4 DNA Ligase. Reactions were performed for 16 hours at 16°C. 
2.2.1.6 Transformation into Escherichia coli (E.coli) 
Entire ligation product was used to transform competent E.coli strain DH10β. 
The whole ligation product was inoculated into 80 µl of cells suspension and heat 
shock was performed in water bath at 43°C for 3 min. Than cells were transferred 
into ice for more than 5 min. Total volume of 100 µl was spread into petri dish 
coated with agar supplemented with 100 µg/µl ampicillin. Petri dishes were 
incubated over-night at 37°C. A control ligation without insert was always 
performed in order to check the vector self-ligation. 
2.2.1.7 Plasmid mini- and maxi-preparation and extraction 
5 to 10 colonies were usually picked up, and inoculated each into 3 ml Luria 
Broth (LB) supplemented with 100 µg/µl ampicillin, and incubated 6 hours at 
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37°C in shaking incubator. Plasmid DNA was extracted using QIAprep Spin 
Miniprep Kit. Plasmid DNA was re-suspended into 50 µl Tris-EDTA. Enzyme 
digestion was always performed to check the ligation product as well as 
sequencing. 
2.2.1.8 Competent cells 
DH10b competent cells for heat shock were prepared growing them in LB agar 
plate without antibiotic selection overnight at 37°C. Day after one single colony 
is picked up and inoculate into 2 ml of LB without antibiotic selection, overnight 
at 37°C. Next day, 500 µl of overnight culture growth are grown into 100 ml LB 
without antibiotic selection at 37°C, until the OD 600 reaches values between 0.6 
and 0.8. Cells are transferred into 50 ml tubes on ice. From this point on, cells 
must be kept cold at all time. After 1 hour cells are spun down at 3500 rpm, 15 
min, 4°C. Pellet is re-suspended in 30 ml ice-cold 100mM CaCl2 / 15 % glycerol 
solution and left on ice 1 hour. Than the solution was spun one more time as 
above and re-suspended in 8 ml ice-cold 100 mM CaCl2 / 15 % glycerol solution 
and left on ice 1 hour. Cell suspension is thus transferred into 1.5 ml tube and 
flash-frozen for 5 min in a mixture of dry ice and 70% Ethanol and stored at -
80°C. 
2.2.2 Standard tissue cultures procedures 
2.2.2.1 Cells cultures 
HTB-94 cells were used to test the ability of the DNA constructs to express the 
transgenes in vitro. Cells were cultured into DMEM with 10% FCS and 1x 
Penicillin/Streptomycin (P/S). Cells were kept into incubator providing constant 
37°C and 5% CO2 pressure. Culture medium was usually changed with fresh one 
every other day. Cells were growth on culture dishes or flasks (Corning 
Incorporated). 
To detach adherent cells from the surface of culture dishes or flasks, trypsin-
EDTA was used. Cells were washed two times with sterile PBS. Cells were 
incubated with trypsin 5 min at 37°C. Complete DMEM was added to neutralize 
enzymatic activity. Cell suspension was transferred into 15 or 50 ml tube and 
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centrifuged for 5 min at 300x g. Supernatant was discarded and cell pellet re-
suspended into fresh medium and seeded according to experimental plan. 
2.2.2.2 Transfection with plasmid DNA 
HTB-94 cells were transfected by electroporation using the Neon Transfection 
System (Invitrogen). 
Cells were washed twice in sterile PBS and detached using trypsin. Harvested 
cells were re-suspended in PBS (without Ca2+ and Mg2+) after centrifugation and 
counted. Aliquots of 2.5x106 cells each were transferred in sterile 15 ml tube. 
Cells were centrifuged once more and re-suspended in 225 µl of Buffer R. 50 µg 
of plasmid DNA were added in a total volume of 25 µl to obtain a final cell 
density of 1.0×107 cells/ml. 100 µl of the cell suspension were loaded in the pipet 
provided in the kit and electroporated. The best electroporation setting was 
empirically determined as: 2 pulses of 20 ms at 1000 v. Electroporated cells were 
transferred in 6 cm dish containing 2 ml of growth medium without P/S. The 
same tip was used to electroporate another 100 µl aliquot of the cells suspension. 
Again the transfected cells were transferred in a new 6 cm dish containing 
medium without P/S. Cells were incubated 24 hours at 37°C. 
2.2.2.3 Transduction with adenovirus 
Adenovirus handling was performed in the specific restricted access “virus room” 
of the Kennedy Institute of Rheumatology (KIR) and according to the department 
safety rules. 
The adenovirus CMV-Cre was present in the KIR virus archive (#205). It was 
initially obtained as a gift and expanded by Dr Fred Tam (Imperial College of 
London). The virus backbone corresponds to the human Adenovirus Type5 
(dE1/E3), and is a well-established tool to deliver high efficient recombination in 
a variety of cells and tissues (Kamei, Ishikawa et al. 2006).   
The virus was designed in order to express the Cre recombinase enzyme from the 
P1 Bacteriophage, modified with a nuclear localization sequence (NLS). A 
cytomegalovirus (CMV) promoter sequence mediates the gene expression. The 
virus construct lacks a reporter gene such as Green fluorescence protein (GFP). 
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After transfection cells were incubated 24 hours and then transferred in the virus 
room. Cells were washed twice in PBS. Adenovirus was diluted in 1 ml of FCS-
free DMEM without P/S in order to have a multiplicity of infection (MOI) of 50 
calculated on the number of cells used for the transfection. Infected cells were 
incubated at 37°C for 2 hours. Cells were washed 3 times in PBS than incubated 
for 48 hours in serum-free DMEM. 
2.2.3 Standard β-galactosidase staining 
 
Table 2.1. Reagents for β-galactosidase staining 
All solution were stored at 4°C up to a maximum of one week. X-gal substrate 
solution was stored at -20°C. 
2.2.3.1 In vitro β-galactosidase staining (cells) 
Cells were washed twice in cold PBS, than incubated in ice-cold fixative solution 
for 4 min, on ice. Fixative was discarded and cells carefully washed 3 times for 5 
min with ice-cold washing solution. Finally cells were incubated at room-
temperature over-night staining solution. 
2.2.3.2 In vivo β-galactosidase staining (embryos) 
Pregnant mothers were intra-peritoneal (IP) injected once with 0.5 ml of 10 
mg/ml tamoxifen at embryonic day E13.5 or E14.5 and sacrificed 24 hours later. 
Embryos were harvested and incubated for 30 min in cold fixative solution at 
room temperature on a rotating shaker. Fixative solution was discarded and 
embryos were washed for 30 min in washing solution at room temperature on a 
rotating shaker. This step was repeated 3 times. Embryos were than incubated 
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over-night in staining solution at room temperature on a rotating shaker. The day 
after embryos were washed in washing solution and transferred to 10% formalin 
solution to preserve the tissues. 
2.2.3.3 In vivo β-galactosidase staining tissues (adult tissues) 
Mice were injected via IP 3 times with 150 µl of 10 mg/ml tamoxifen and 
sacrificed 2 weeks afterwards.  Several organs and tissues were collected. More 
in details to hind limbs, they were clean from most of muscular tissues and both 
cruciate ligaments and tendons were cut in order to expose tibia plateau and 
femur condyles. Samples were incubated for 90 min in fixative solution at room 
temperature on a rotating shaker. Fixative solution was discarded and samples 
were washed three times for 30 min each in washing solution at room 
temperature on a rotating shaker. Samples were incubated over-night in staining 
solution at room temperature on a rotating platform. The Day after, tissues were 
washed in washing solution and transferred to 10% formalin solution to preserve 
the tissues. 
2.2.3.4 Transgenic Mouse analysis 
2.2.3.4.1  Collection of embryos from pregnant mothers. 
Unless otherwise stated, mice were collected at the E14.5 stage of gestation (14.5 
dpc). All the procedures occurred in ice cold PBS. Pregnant mother was 
sacrificed by vertebra dislocation according to local rules. Once the cadaver was 
set up supine, the belly was open using sterile forceps, and the uterus isolated. 
Embryos were removed from the uterus and cleaned from the yolk sack. Embryos 
were briefly washed in ice-cold PBS and transferred in ice-cold Fixative solution 
for X-gal staining. 
2.2.4 Standard Western Blot analysis protocols 
2.2.4.1 Samples collection 
Adult 8 weeks-old mice were injected with tamoxifen and sacrificed 2 weeks 
afterwards. Muscle tissues were removed using a sterile scalpel. Cruciate 
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ligaments and tendons were cut in order to expose tibia and femur articular 
cartilage ends. Epiphyses were detached from the long bones inserting the scalpel 
in the growth plate and twisting. The total of four epiphyses were collected from 
the hind limbs of each mouse and pulled together. Samples were quickly frozen 
in liquid nitrogen and stored in -80ºC freezer when not used immediately. 
2.2.4.2 Extraction of proteins from mouse epiphysis 
Samples were pulverized using the freeze-fracturing method and a bio-pulveriser 
pistol was used. Samples were re-suspended in Tissue Protein Extraction Reagent 
supplemented with proteinases inhibitors (Pierce). T-PER was used at 10 µl/mg 
of tissues weight. Tissues suspensions were vortexed for 30 sec and rested in ice. 
In order to facilitate the proteins extraction, tissues suspensions were sonicated 3 
times on a 30sec/30sec on/off cycle in a 4ºC water bath. Samples were vortexed 
for 30 sec and centrifuged at 10000 g for 5 min in a refrigerated centrifuge. 
Supernatant was collected and transferred in a clean tube. In order to evaluate the 
protein concentration of the samples the BCA Protein Assay was used according 
to the manufacturer’s instructions. 
2.2.4.3 Standard histological analysis protocol 
Dissected knee tissues either collected fresh or after X-gal staining, were kept in 
10% formalin solution for 48 h. Tissues were decalcified in 10% EDTA solution 
pH 7.4 for 4 weeks, changing solution every week.  
Tissues were than embedded in paraffin wax to be sectioned for histological 
analysis. The automated, under vacuum tissue processor was set up as follows: 
tissues were dehydrated sequentially in 80% ethanol for 30 min, 90% ethanol for 
30 min, and 100% ethanol 3 times for 30 min. Then they were put in 50% 
ethanol/ 50% xylene for 15 min, then 100% xylene for other 15 min. Finally, they 
were placed in molten paraffin wax at 65°C for 4-8 hours. They were then 
transferred to a plastic mold containing paraffin wax and left to set. Unless 
otherwise stated, all steps were performed at room temperature. The wax blocks 
were then cut along the coronal plan at 10 µm. All the embedding and cutting 
procedures were carried out in the Histology Laboratory of the Kennedy Institute 
of Rheumatology. 
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2.2.4.4 Immunofluorescence techniques 
Selected histological sections were heated at 60°C for at least 40 min (or until 
paraffin was melted) to bond the tissue to the glass. Three washes in xylene for 5 
min each assured complete removal of paraffin wax from the sections. Sections 
were rehydrated in solution of decreasing concentration of ethanol: 100%, 70%, 
30% and than rested in tap water. An antigen retrieval procedure was performed 
to expose the epitopes on the samples. Slides were treated with bovine testicular 
hyaluronidase 0.1 mg/ml in PBS for 45 min at 37°C, in a wet chamber to prevent 
excessive evaporation. Sections were washed 3 x 3 min in TBS-T at room 
temperature. Non-specific binding of primary or secondary antibodies was 
prevented by incubation in TBS-T/ 5% BSA, 1% Goat Serum for 1 h at room 
temperature. Sections were incubated in primary antibody and DAPI (for nuclei 
staining) diluted in blocking buffer ON at 4°C in a wet chamber. After 3 x 3 min 
washes in TBS-T sections were incubated in secondary antibody diluted in 
blocking solution for 1 h at room temperature. Incubations omitting the primary 
antibody were used as negative control. After three washes of 5 min each in TBS-
T, a final was of 5 min was performed in TBS. Slides were air dried and mounted 
with ProLong Gold Antifade Reagent. Sections were observed using Ultraview 
confocal microscope (PerkinElmer Life Sciences) with a 60x objective lens. 
2.2.5 Quantitative reverse-transcription PCR (Q-RT-PCR) 
2.2.5.1 Isolation of articular cartilage 
Adult 8 weeks-old mice were injected with tamoxifen and sacrificed 2 weeks 
afterwards. Muscle tissues were removed using a sterile scalpel. Cruciate 
ligaments and tendons were cut in order to expose tibia and femur facing ends. 
Articular cartilage was accurately shaved off the bone surface using a micro-
rongeur surgical tool (Friedman-Pearson, cat# 16120-14). Articular cartilage was 
transferred in RNAlater, frozen in liquid nitrogen and stored at -80°C. Only the 
lower limbs of each mouse were processed, so each samples contained cartilage 
from two tibia plateaus and two femoral condyles. 
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2.2.5.2 Extraction of RNA from knee cartilage 
Total RNA was extracted from mouse articular cartilage samples using the 
RNeasy Micro Kit. The manufacturer protocol was partially modified by Dr 
Anastasios Chanalaris (KIR) increase the RNA quality from small amount of 
articular cartilage.  
RNAlater was removed from the tubes and samples were resuspended in 150 µl 
of 1% β-Mercaptoethanol/RTL lysis buffer. In order to destroy the cartilage 
structure samples were first sonicated 2 x 15 s (20 s rest), on ice, and than, after 
addition of 5 µl of Proteinase K and 295 µl of RNase-free H2O, incubate at 55°C 
20 min. Samples tube were centrifuged in a bench centrifuge at 1000 g for 3 min. 
A total of 400 µl of supernatant was transferred into a clean tube and mixed with 
225 µl Ethanol 100%. The whole solution containing nucleic acids was than 
transferred in the RNeasy Micro column and centrifuged at 7000 g for 15 s. 
Column was washed with 350 µl of RW1 buffer and DNase I treatment 
performed in column, to degrade genomic DNA. The column was washed again 
with 350 µl RW1. Two more washes with 500 µl RPE buffer and with 500 µl 
ethanol 80% were performed to prepare the RNA for elution. Finally RNA was 
eluted in 14 µl RNAse-free water. A NanoDrop Spectrophotometer was used to 
assess concentration and purity of RNA samples (Table 2.2). 
2.2.5.3 Reverse-Transcription of mRNA (RT-PCR) 
The TaqMan system was the method chosen for the real-time PCR assays. This 
method principle relies on the 5´–3´ exonuclease activity of Taq polymerase to 
cleave a probe during hybridization to the complementary target sequence. The 
probe is designed to anneal a region within the primers set and is dual-labeled 
with a fluorophore and a quencher, the latter quenching the fluorescence emitted 
by the former. When the Taq polymerase hydrolyses the bond between the probe 
and the fluorophore, this is released and is free to emit fluorescence. TaqMan 
method allows obtaining a direct correlation between number of copies of the 
gene of interest and the fluorescence signal. 
cDNA was generated using the ‘High Capacity cDNA Reverse Transcription 
Kit”. Briefly, for each RNA sample, 500 ng of RNA was reverse transcribed to 
cDNA in a 20 µl reaction according to manufacturer instructions. The RT 
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reaction was made of four steps: 10 min 25°C, 120 min 37°C, 5 min 85°C and 
cool down to 4°C. cDNA was diluted 1:4 and stored at -20°C. 
 
Table 2.2. Example of RNA quantification isolated from adult mice knees, obtained using 
NanoDrop. Abs 260/280: ratio of absorbance at 260 nm and 280 nm; values >2 denote high 
purity for RNA. 
2.2.5.4 Real-Time PCR (qPCR) 
cDNA was examined by Real-Time PCR using TaqMan technology. TaqMan 
primers/probe sets for TIMP3 (Hs), Acan (Mm00545794_m1), Hprt 
(Mm00446968_m1) and lacZ were from Applied Biosystems (USA). The ABI 
HT9000 thermal cycler and the ΔΔCt method of relative quantitation were used 
for mRNA quantitation using Hprt as internal control. For the ΔΔCt calculation 
to be valid, the amplification efficiencies of the target and reference must be 
approximately equal. This was assessed by analysis of the ΔCt of dilution of the 
cDNA, which showed a similar slope for the targets and the Hprt reference. 
2.2.6 Generation of transgenic mice 
2.2.6.1 General notes 
Transgenic mice were generated in collaboration with Dr Ke Liu from the 
Kennedy Institute of Rheumatology (KIR). Dr Liu is the transgenic expert at 
Kennedy and performed all pronuclei harvesting, DNA microinjections and 
transfer in foster mothers. My contribution in transgenic generation was restricted 
to provide high quality DNA, help in hormone stimulation, and post surgical 
caring. For all procedures, C57BL10 x CBA/J F1 mice were used. All techniques 
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performed on animals were licensed under the Animals (Scientific Procedures) 
Act 1986, personal license number (PIL) 70/20608 and project license number 
(PPL) 70/7288. 
2.2.6.2 Transgenic media 
M2 and M16 media were purchased from Sigma and made up according to 
manufacturers’ instructions. M16 was covered in mineral oil and incubated at 
37°C in 5% CO2, 95% air to simulate in	vivo conditions during use. M2 was kept 
at room temperature. 
2.2.6.3 Preparation of DNA for microinjection 
Fragments of linear DNA for microinjection were isolated from their plasmid 
vectors with the appropriate restriction enzymes and gel-purified in EtBr free gels 
without UV exposure. This was done by running two identically digested samples 
alongside each other on an EtBr free gel, cutting the gel vertically between the 
two samples, staining one of the halves in an EtBr solution and exposing this half 
to UV to mark by gel excision the location of the desired band. Finally, the 
desired band was cut from the other non-stained half using the stained gel for 
guidance. The DNA was then purified from the gel using spin columns. The 
concentration of the DNA was established, diluted to 2 ng/µl in embryo water 
from Sigma, and stored at -20°C. 
2.2.6.4 Preparation of egg donors by superovulation 
Superovulation was performed on F1 females between 4-6 weeks of age. On day 
one, 5 International Unites (IU) of follicle stimulating hormone (folligon) was 
administered to each mouse via IP injection. On day 3, approximately 46 hours 
later, 5 IU luteinising hormone (chorulon) was administered to each mouse via IP 
injection. Following this injection, the mice were mated with F1 fertile males 
overnight. On the morning of day 4, copulation plugs were checked to identify 
mated females. From these, oviducts were removed and dissected in M2 media 
giving an average of 10-15 eggs per oviduct. These were removed by forceps and 
transferred into clean media. Cumulus cells were removed by treatment with a 
few drops of hyaluronidase (300 µg/ml) in M2. The eggs were gently shaken 
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until the cumulus cells had visibly detached from the egg surfaces (>4 min). They 
were thoroughly rinsed, and transferred to M16 media to be incubated for 1-2 
hours. 
2.2.6.5 Injection of fertilised eggs 
Injection of fertilised eggs was done approximately 72 hours after 
superovulation. This is described in Hogan (Hogan 1994). Undamaged eggs were 
transferred to clean M16 and incubated until their transfer into pseudo pregnant 
females. 
2.2.6.6 Transfer to pseudo pregnant recipients 
Mating with vasectomized CD1 males overnight on day 3 generated pseudo 
pregnant CD1 female mice. Females with copulation plugs were selected and 
used 0.5 day post-coitum. Anaesthetic solution was prepared mixing 50 µl 
hypnorm, 50 µl hypnoval and 100 µl sterile H2O. Mice were anaesthetized via IP 
injection of 200 µl of anaesthetic solution. Microinjected eggs, at 1 cell stage, 
were transferred through the infundibulum to the oviducts. Each pseudo pregnant 
female received 20-30 eggs. 
2.2.7 Management of mouse colonies 
2.2.7.1 Common husbandry procedures 
Mice underwent regular health monitoring, a microbiological surveillance 
programme by competent persons checking cages twice per day. These checks 
ensured that all sick or injured animals were identified and appropriate action 
took. 
Breading pairs were set up choosing animals between 8 weeks old and 6 months 
old. In order to maintain the transgenic lines, mice screened positive by PCR 
genotyping were mated initially to C57BL/6 wild type mice, and further between 
each others in order to obtain transgenic homozygous. 
Transgenic mice responsible to tamoxifen were generated breading mice 
screened positive for the transgene to ROSA-Cre (B6.129-
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Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J mice, The Jackson Laboratory). Progenies 
were screened for both the genetic background. 
2.2.7.2 DNA extraction from mouse tissues for genotyping 
For genotyping purpose ears biopsy from adult mice and tail fragment from 
embryos were collected. Tissues were processed using the REDExtract-N-Amp 
Tissue kit from Sigma. 
2.2.7.3 Genotyping by PCR 
Multiplex PCR was performed for screening of transgenic mice (adapted from 
Wayne Barnes, Washington University in St. Louis). Primers were designed to 
target the lacZ gene (in the expression vector), the Cre recombinase gene and the 
mouse gene fabp1 (fatty-acid-binding protein) (used as internal control). All 
primers stock solutions were diluted to a working dilution of 10 pmol. Each PCR 
reaction contained the following amount of primers: 
2 µl each target primer (lacZ or Cre) 
1 µl each internal control primer (fabp1) 
A 2-step PCR program was used and is described in the following table: 
 
Table 2.3. Thermo cycler settings for genotyping 
Nucleotide sequences of all primers’ set are shown in the following table: 
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Table 2.4. Nucleotide sequences of primers used for genotyping 
The total PCR reaction volume of 20 µl was electrophoresed in a 2% Agarose 
gel. Figure 2.1 is a representative genotyping results. All samples containing 
genomic DNA show a 200 bp band. Only samples from transgenic mice show an 
extra band at 400 bp. No template control (NTC) does not show any band 
(Figure 2.1). 
 
Figure 2.1. Genotyping by Multiplex PCR. Representative genotyping screening by PCR 
analysis of wildtype and transgenic mice. Primers sets to lacZ gene and fabp1 were used. All 
samples but NTC show the 200 bp band related to the fabp1 used as internal control. Only sample 
2 and the positive control show a 400 bp band related to the lacZ gene. NTC: no template control. 
2.2.7.4 Surgical induction of OA through the destabilisation of the medial 
meniscus (DMM) model 
Mice were anaesthetized via IP injection of Hypnorm and Hypnovel. After 
shaving of the ventral portion of the right knee, a midline incision was made over 
the ventral aspect and the medial compartment of the knee. The medial meniscus 
was identified, and using an ophthalmic scalpel, its anterior horn was released by 
sharp dissection of the attachments to the tibia plateau. Mobility of the anterior 
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half of the medial meniscus was confirmed by displacement with forceps. The 
para-patellar incision was closed with an absorbable suture (Ethicon, USA), and 
the skin closed with fine non-absorbable sutures (Ethicon, USA). A specialized 
technician at the Kennedy Institute of Rheumatology performed all the DMM 
surgeries. 
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Chapter 3  
Design and generation of  
aggrecan-driven CreERT2 mice 
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I have divided the ‘Results’ section into four chapters. Each chapter contains an 
overview of the experimental work (background), a report of the data itself 
(results) and finally a discussion of the data evaluating the findings (discussion). 
The main aim of the Chapters 3 and 4 is to illustrate the design and production of 
expression vectors using sequences from the mouse aggrecan enhancer. The 
designed vectors will drive expression in mouse tissues of different target genes: 
the Cre-recombinase or the human TIMP-3 and its mutant [-1Ala]TIMP-3. In 
Chapter 5 I will describe the design of a vector to express TIMPs not only in the 
articular cartilage but also in other tissues, including the synovial membrane of 
knee joint and the subchondral bone. To achieve this result I used the promoter of 
the mouse ubiquitin C gene. Finally in Chapter 6 I will illustrate preliminary 
results of surgical-induced osteoarthritis in some transgenic lines. 
3.1 Background 
The first aim of my thesis was to develop an effective inducible Cre/Lox system 
to target articular cartilage and monitor its expression in real-time. I was well 
aware that there were at least two CreERT2-expressing cartilage-specific mice 
already existing, however I decided to generate a new one for four reasons. First, 
some data from literature suggested that the promoter of the Collagen type II 
gene could not be so effective in old mice (more than 6 months of age); second, 
that the Aggrecan knock-in from Henry would not allow to observe the 
expression in vivo; third, my supervisor Dr Bou-Gharios and I were interested to 
investigate if the Aggrecan enhancer sequences identified by Lefebvre’s group 
(named A1, A2 and A3) were able to regulate the expression of Aggrecan both 
spatially and temporally; fourth, because I wanted to investigate the expression of 
TIMP-3 in cartilage I could have used the same genetic elements for both the 
transgenic mouse systems. 
Conditional overexpression or inactivation of genes in the adult mouse has 
become the method of choice when investigating the role of a genes of interest in 
vivo (Branda and Dymecki 2004). This recombination system has been made 
possible by the advent of the Cre/loxP technology and more recently the similar 
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Flp/FRT technology (Dang and Perrimon 1992, Lee, Moding et al. 2012). The 
Cre recombinase system has become the tool of choice to conditionally activate 
(“gain-of-function”) or inactivate (“loss-of-function”) gene expression in a 
temporal, spatial, or tissue-specific manner. Cre recombinase efficiently excises 
DNA flanked by repeated loxP recognition sites both in cultured cells and in 
mice (Sauer and Henderson 1988, Orban, Chui et al. 1992). A major 
enhancement was achieved by conditional gene targeting based on inducible 
activation of the Cre recombinase obtained by fusing the Cre to the ligand-
binding domains (LBDs) of steroid receptors (Metzger, Clifford et al. 1995).  
Subsequent mutations were introduced into the LBDs of chimeric Cre 
recombinase to abolish the activation by natural ligands and to increase affinity to 
the synthetic tamoxifen. Feil and colleagues generated a chimeric protein where 
the Cre recombinase has been fused to a mutated ligand-binding domain of the 
human oestrogen receptor (ER) resulting in a tamoxifen-dependent Cre 
recombinase, Cre-ERT, which is activated by 4-hydroxytamoxifen (4-OHT), but 
not by estradiol. The chimeric protein is thus trapped in the cytoplasmatic 
environment until it binds to the receptor’s ligand (Feil, Brocard et al. 1996) 
(Feil, Brocard et al. 1996). Subsequent mutation studies on the ligand-binding 
site in the ER portion, allowed to generate chimeric protein highly specific for the 
4-OHT (Feil, Wagner et al. 1997, Indra, Warot et al. 1999). 
As I will show in the current and next chapters, a tissue-specific Cre deleter was 
generated to be able to study the effects of several genes in articular cartilage. At 
the same time a cartilage-specific transgenic mouse was generated to work 
together with the well-described ROSA-Cre recombinase mouse line (Grover and 
Roughley 2006). 
My aim was to achieve articular chondrocyte-specific expression. Remarkably 
two target genes were identified to be able to allow restricted expression in the 
articular cartilage chondrocytes: Col2a1 and Acan. As discussed in the 
Introduction chapter those are the most abundant structural proteins in the adult 
articular cartilage and are very likely to be responsible for maintaining the whole 
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structure. Ever since type II collagen was discovered as a major component of 
chick cartilage by Miller and Matukas (Miller and Matukas 1969), it has been 
considered an hallmark for chondrocyte differentiation and a chondrocyte-
specific marker. However, later studies demonstrated that type II collagen was 
expressed much earlier than the onset of chondrogenesis, which occurs at the 
time of condensation of the mesenchyme. Moreover type II collagen has been 
detected in numerous tissues that never undergo chondrogenic differentiation. 
Expression of Col2a1 mRNA was also observed in notochord that may be 
responsible for inducing chondrogenesis in somitic mesoderm, neural retina, the 
corneal and conjunctival epithelia and sclera of the developing eye. Transient 
expression was also found in the heart at 9.5-12.5 days, and the epidermis at 
10.5-14.5 days, the inner ear at 14.5 days and the fetal brain from 9.5-14.5 days. 
(Cheah, Lau et al. 1991). In 2000 Behringer’s group generated a Cre-deleter 
transgenic mouse using the promoter of the collagen type II (Ovchinnikov, Deng 
et al. 2000) . Both in my experience and in literature, the expression of collagen 
type II is sustained during the pre-natal development until early adult age (4 to 6 
weeks of age). Following that, expression drops to lower levels as suggested by 
Chambers, although in unpublished data (Chambers, Kuffner et al. 2002). 
Although the decrease of expression is a physiological event and does not affect 
the structure of the adult joint, I foresaw a caveat in use the promoter for adult 
expression of the transgenes of interest. Moreover some authors detected Cre 
recombinase expression in kidney epithelium in Col2-Cre mice during 
development, which reflects the transient expression of the endogenous Col2a1 
gene in the embryonic renal tubules (Kolpakova-Hart, Nicolae et al. 2008). As an 
alternative approach several authors investigated the capacity of aggrecan 
response elements to drive cartilage specific expression in mouse cartilage since 
aggrecan is a major extracellular matrix proteoglycan of both the growth plate 
and articular chondrocytes. Henry et al in 2009 cloned the Cre recombinase 
coding sequence downstream of the mouse aggrecan gene achieving cartilage 
specific deletion (Henry, Jang et al. 2009). In 2008 Han and Lefebvre identified a 
400-bp long cis-acting element upstream of the aggrecan mouse gene, recognized 
by Sox9 and sufficient to drive cartilage specific expression (Han and Lefebvre 
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2008). I decided to take advantage of these findings to generate an aggrecan-
driven cartilage specific transgenic mouse. 
As mentioned above an inducible system allows one to achieve temporal 
regulation to delete or overexpress target genes. Engineering the Cre recombinase 
enzyme was the key to obtaining this feature. 
In the first inducible Col2a1-CreERT generated (Grover and Roughley 2006) 
transgene was not highly expressed in adult (Nakamura, Nguyen et al. 2006). 
However, more recent work by Chen and colleagues presented a Col2a1-driven 
CreERT2 transgenic line in which they achieve efficient tamoxifen induced 
recombination in articular cartilage in older animals (Chen, Lichtler et al. 2007) . 
In 2008, Han and Lefebvre identified an enhancer upstream of the mouse 
aggrecan gene that was recognized by Sox9, L-Sox5 and Sox6 (Han and 
Lefebvre 2008). When this enhancer was used to generate lacZ reporter mouse, 
the transgenic mouse stained for β-galactosidae in all cartilaginous tissues. Henry 
et al (2009) generated a deleter mouse line by knocking-in the CreERT2 
downstream of the stop codon of the endogenous mouse aggrecan gene creating 
Agc1 tm(IRES-creERT2) (Henry, Jang et al. 2009). 
3.2 Results 
3.2.1 Design and construction of expression vectors 
To design and generate our own cartilage-specific Cre deleter mouse strain, I 
took advantage of Han and Lefebvre paper where they describe the design of a 
construct containing four tandem repeats of the sequence identified in the mouse 
‘aggrecan enhancer’ (which they named A1), fused downstream of the Col2a1 
minimal promoter (-309 / +308 base pairs relative to the mouse Col2a1 
transcriptional start site) (Figure 3.1 A). 
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The original vector containing Col2-4xA1 sequence was obtained from 
Veronique Lefebvre’s group (Han and Lefebvre 2008) As described in their 
paper, the A1 sequence was amplified by PCR performed on 129 mouse genomic 
DNA. Four tandem copies were cloned into a LacZ reporter plasmid containing a 
Col2a1 promoter sequence that was previously identified to drive chondrocyte 
expression in mouse embryos (Zhou, Garofalo et al. 1995). 
I designed a three-steps plan to construct the final vector (Figure 3.1 B). 
- The firefly Luciferase reporter gene was cloned in a pIRES plasmid, 
downstream of the IRES sequence and upstream of a polyA DNA 
sequence. The Luciferase gene sequence and pIRES plasmid belong to the 
Matrix Biology plasmids archive at KIR.  
- The CreERT2 fusion gene was lifted from its original plasmids (Feil, 
Wagner et al. 1997) and cloned upstream of the IRES sequence of the 
modified pIRES plasmid.  
- The Col2a1-4xA1 DNA sequence was lifted from the original vector and 
cloned upstream of the CreERT2 sequence in the modified pIRES 
plasmid. 
The final construct was named Col2a1-4xA1-CreERT2 (Figure 3.1 B). 
In the CreERT2 the Cre enzyme has been fused to a mutated ligand-binding 
domain of the human oestrogen receptor (ER) resulting in a tamoxifen-dependent 
Cre recombinase, Cre-ERT2, which is activated by tamoxifen, but not by estradiol 
or endogenous hormones (Feil, Brocard et al. 1996, Feil, Wagner et al. 1997). 
The new vector featured an IRES sequence and the firefly (Photinus pyralis) 
luciferase reporter gene. The advantages of using the firefly luciferase as a 
reporter gene are the high sensitivity in detection of expression of the gene, the 
absence of luciferase activity inside most cell types, the wide dynamic range, 
rapidity and low costs. Also, the protein does not require any posttranslational 
modification to be enzymatically active and is not toxic in high concentrations in 
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vivo (de Wet, Wood et al. 1987). The IRES sequence ensured the transcription of 
bi-cistronic mRNA in which two proteins are translated from one mRNA 
sequence. The expression and recombinase activity of this construct was tested 
and used to generate transgenic mice for cartilage specific Cre-mediated deletion 
of floxed sequences (Lo Cascio, Liu et al. 2013). The DNA construct was 
transfected into embryonic cells isolated during development from embryos at 
11.5 days post coitum of ROSA26-lacZ reporter mouse (Rosa26R). This latter 
mouse expresses β-galactosidase after Cre-mediated excision of a transcriptional 
STOP cassette, knocked in the ROSA26 locus (Grover and Roughley 2006). In 
this system the enzyme Cre recombinase deletes the transcriptional STOP, than 
β-galactosidase is expressed and converts its substrate (X-gal), in the presence of 
iron, into blue staining. The staining occurs only in cells expressing the Cre 
recombinase enzyme. In order to activate the Cre recombinase enzyme, 4-
Hydroxytamoxifen  (4-OHT) was added to one of the transfected cell cultures 
(PBS was added as control) for 48h. 4-OHT is the metabolic product of the 
tamoxifen that in mammals is metabolised by cytochrome P450 in the liver to the 
active form. Because this activation process is missing in cell cultures, the active 
4-OHT has to be used. Transfected cells were fixed and X-gal staining showed 
that in the presence of tamoxifen, the majority of cells were expressing β-
galactosidase (Figure 3.1 C), indicating that the inducible construct can remove 
the floxed transcriptional STOP in vitro. 
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Figure 3. 1. Schematic diagram of the Col2a1-4xA1-CreERT2 expression vector and its 
testing in vitro. A: Diagram of the Acan gene showing the locations (in parentheses) and sizes of 
A1, A2, and A3 elements. The horizontal line represents nonexonic sequences. Black boxes with 
numbers underneath represent exons. The arrow symbolizes the start of transcription, and 
AATAAA indicates the polyadenylation site. B: Vector consists of a Col2a1 minimal promoter 
(Col2) plus four tandem repeats of mouse aggrecan enhancer A1; CreERT2 fusion protein; IRES; 
Firefly Luciferase coding sequence; polyA sequence. Ampicillin resistance gene is also indicated 
(Amp). Arrows denote the direction of transcription. E.coli origin of replication is not shown. 
IRES: internal ribosome entry site; polyA: polyadenylation sequence. C: Representative X-gal 
staining. Mesenchymal cells previously isolated from E10 ROSA Reporter embryos were 
transfected with the Col2a1-4xA1-CreERT2 expression vector. Cells were incubated either in 
PBS (left) or in 4-OH tamoxifen (right) for 48h. Cells were fixed and X-gal substrate added. Only 
cells treated with 4-OH tamoxifen showed blue staining. Graph on the right is an esteem of the β-
gal positive cells. 
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3.2.2 Generation of transgenic mice 
In order to generate a transgenic mouse expressing this construct, the linearized 
plasmid was injected in the pro-nucleus of a one day fertilised egg. Founder 
animals were identified by genotyping and mated with Rosa26R mouse to be 
tested for Cre activation. Pregnant mothers were given 3 mg tamoxifen and 
1.5mg of progesterone (to counteract the mixed oestrogen agonist effects of 
tamoxifen injections, which can result in late foetal abortions in pregnant mice) at 
different times during development (E13.5 to E16.5) and sacrificed 24 hours 
later. At each time point, embryos were harvested and stained for β-galactosidase. 
The results showed that three lines out of twenty positive were able to delete the 
transcriptional STOP and express the β-galactosidase albeit with varying level of 
luciferase activity and number of chondrocytes that can efficiently delete in adult 
chondrocytes. In Figure 3.2 are shown representative images of the line that 
showed highest expression. Blue staining was observed in fore and hind limbs at 
E13.5 (Figure 3.2 A, left panel, arrows). At E14.5, the transgene expression is 
more visible in the limbs and the developing ribs (Figure 3.2 A, middle panel). 
By E15.5 almost all the cartilaginous centres were stained, including the nasal (n) 
and otic (o) region, as well as, ribs (r) and all developing vertebra down to the tail 
(t) (Figure 3.2 A, right panel). E16.5 embryos were de-skinned to show 
expression in the head region where the base of the trachea and the mandible 
were stained with X-gal (Figure 3.2 B). The skeletal elements were well defined 
and stained bone formation of the torso including the developing clavicles 
(Figure 3.2 C, c), the forelimbs developing bones, such as the humerus (h) radius 
(r) and ulna (u) and the forming digits (*). The ribs, sternum and the developing 
vertebra of the spine were also intensely stained (Figure 3.2 D, arrows). 
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Figure 3.2. Inducible expression of Cre recombinase in adult double transgenic mice 
confirmed by X-gal staining. A-D: Representative whole-mount Col2a1-4xA1-CreERT2 x 
ROSA26R embryos expressing β-galactosidase (blue staining). A: X-gal staining can be seen in 
the developing embryo at E13.5 in limbs (arrows), E14.5 and E15.5 the nasal region (n), 
developing ear (e) and ribs (r) as well as vertebra of the tail (t). B-D: At E16.5 the mouse was de 
skinned and dissected to reveal the staining at base of trachea, (B, arrow) and mandibles (B, *). 
The forelimbs and shoulder cartilaginous staining is seen in developing clavicles (C,c), humerus 
(C,h) radius and ulna (C, r and u) and in digits (C, *). Staining is also seen in sternum (D, s) and 
developing dorsal ribs (D, *) and vertebra of spine (D, arrows). 
Expression of Cre recombinase was tested in adult mice at eight weeks of age. 
The mature double transgenic mice were injected intra-peritoneally three times, 
every other day, with 2 mg of tamoxifen and sacrificed one week after last 
injection. The skeleton was isolated, fixed and stained for β-galactosidase 
overnight. Whole mount isolated tissues and histological cross-sections showed 
high levels of β-galactosidase expression only in the tamoxifen injected double 
transgenic animals. These data prove that the inducible, conditional Cre 
recombinase under the control of Acan enhancer is activated, as expected, in the 
mouse adult tissues (Figure 3.3). The expression was evident in the knee joint 
tibia plateau (Figure 3.3 A). The condyles, as well as the fibrocartilage of the 
patella and menisci were stained (Figure 3.3 B-C). Histological sections show 
the expression of the transgene in the majority of the chondrocytes above the 
tidemark (Figure 3.3 C). There was no expression of the transgene in calcified 
cartilage. The majority of the chondrocytes in ribs were also stained with X-gal 
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(Figure 3.3 D-E). Isolated whole mount tails and longitudinal sections stained 
with X-gal, shown staining in the intervertebral disc nucleus pulposus (np), 
annulus fibrosis (af) showing as punctate staining of cells expressing transgene 
and in the growth plate (Figure 3.3 F-G). Tendons did not stain uniformly. 
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Figure 3.3: Inducible expression of Cre recombinase in adult double transgenic mice 
showed by X-gal staining. Col2a1-4xA1-CreERT2 mice mated with Rosa26R mice were given 
tamoxifen at eight weeks and stained for β-galactosidase a week later. A: Isolated tibia plateau 
shows staining only in the presence of tamoxifen (right) compared to just vehicle (left). B: Blue 
staining was observed in condyle (c) and patellar cartilage (p). C: Coronal section of the knee 
shows chondrocytes in the uncalcified cartilage (ca, above the tidemark, t) express the transgene 
and as well as cells in meniscus (m). D-E: Rib cage shows blue staining in whole mount (D) and 
in cross section (E). F-G: Blue staining was observed in the vertebral rings of the tail. G: 
Histological coronal sections of tails highlight the cells stained in the nucleus pulposus (np) and 
annulus fibrosus (af).  By comparison, only occasional cell stained blue in tendon (t). 
The added advantage in this mouse model is the inclusion of the firefly (Photinus 
pyralis) luciferase coding sequence downstream to the Cre recombinase, allowing 
the visualisation of expression in real time, in live animals. The chemical reaction 
catalysed by firefly luciferase takes place in two steps and the final product is the 
oxydation of the substrate luciferin to oxyluciferin. Light is emitted because 
oxyluciferin jumps in an electronically excited state and when it returns to the 
ground state, it releases a photon of light. Compared to other detection systems 
such as fluorescence, luciferase offers inferior resolution in tissues, but produces 
a higher level of energy, allowing better penetration of tissues, and thus 
detection. 
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Upon IP injection, the D-luciferin is slowly absorbed into circulation, perfuses 
into tissues and is excreted by the kidneys, because is not metabolised. The 
emission plateau phase usually occurs at 15 min post luciferin injection and lasts 
for 15-20 min. Signal detection was performed between 20 and 30 min post 
injection in a Kodak In Vivo FX Pro machine. Bioluminescence was detected in 
the fore and hind limbs, as well as, the tail. The most discernable luciferase signal 
was in the knees, heels and metatarsals. Bioluminescence was also detected in 
every vertebra of the tail as well as the cartilage of the sternum (Figure 3.4 A). I 
studied the levels of luciferase expression of five mice, from two weeks until 
eight weeks of age. Every two weeks mice were anaesthetized and injected with 
D-luciferin. Because in the DNA construct the Luciferase coding sequence was 
under the control of the Aggrecan enhancer, it is possible to speculate that in both 
knees and in the tail vertebra the aggrecan expression was reduced between two 
and four weeks of age but remained constant thereafter (Figure 3.4 B-C).  
At 10 weeks of age the same mice were subjected to a surgical procedure (DMM, 
Destabilization of the Medial Meniscus) that induces the development of 
osteoarthritis-like changes in the medial compartment of the knee (Indra, Warot 
et al. 1999). The rational was to evaluate whether the onset of osteoarthritis 
would induce changes in expression of Aggrecan gene, and thus luciferase, in the 
operated knee (right knee) compared with the left (un-operated) knee. 
Luminescence was measured from the right and the left knee over eight week 
period post-operatively (Figure 3.4 D) and the amount of luminescence emitted 
from the right knee was compared to the left knee as well as the third vertebrae 
from the base of the tail. The results showed that there is no significant change in 
luminescence in vivo between the operated and un-operated knees for the 
duration of the experiment (Figure 3.4 D). Using quantitative PCR, we found 
that there was no significant change in the Acan mRNA level between the two 
knees at 2, 4, and 8 weeks post-surgery, confirming the bioluminescence 
observations (Figure 3.4 E). 
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Figure 3.4. Bioluminescence as a tool to track expression in vivo. Double transgenic mice were 
anesthetised and injected with D-luciferin. A: luminescence can be observed in joints of the 
limbs, tail and cartilage of the sternum. B: The expression was tracked in vivo showing that 
transgene level decreased at weaning age (4wks) and remained steady thereafter. C-D: 
Transgenic mice that have undergone DMM at ten weeks of age (n=5 in each group) were tracked 
every other week for the following eight weeks. Bioluminescence was plotted in injured, right 
knee and left untreated knee and compared with tail expression. E: qPCR analysis of endogenous 
Acan gene in articular cartilage at 2, 4, and 8 weeks after DMM show no significant difference in 
Aggrecan mRNA level between right (operated) and left (un-operated) knees (n=3 in each group). 
Data shown that transgene expression is stable over eight weeks after DMM in both knees. 
The osteoarthritis-like injury induced by the surgical model was validated. Five 
mice were sacrificed at eight weeks after DMM. The knee joints were removed, 
fixed and embedded in paraffin wax. Coronal sections were cut and stained with 
Safranin-O and fast-green, and scored using the Osteoarthritis Research Society 
International (OARSI) scoring system (Glasson, Chambers et al. 2010) (Table 
3.1). I and Dr Darren Plumb at KIR blind-scored the same histological sections. 
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Table 3.1. The recommended semi-quantitative scoring system. (Adapted from Glasson et al., 
2010) 
Eight consecutive sections per sample were scored and summed. High 
magnification of the medial compartment shows areas of fibrillation with loss of 
Safranin-O, indicating loss of proteoglycan in the right operated knee (Figure 3.5 
B,D) compared with the left (un-operated) (Figure 3.5 A,C). This is also 
reflected in the histologic scores of all five mice where it shows significant 
increase P<0.05 in degradation of articular cartilage in the medial tibia plateau of 
right operated knees of transgenic mice at 8 weeks after DMM surgery (Figure 
3.5 E). 
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Figure 3.5. Photomicrographs of representative histologic sections of knee joints, eight 
weeks after DMM. A-B: Low magnification micrographs of the left (un-operated) and right 
(operated) knees. C-D: Higher magnification micrographs of the medial compartment (of A, B 
respectively) shows areas of fibrillation (arrows) with loss of Safranin O–fast green staining, 
indicating loss of proteoglycan in the operated knee only. E: Histologic scores of transgenic mice 
at 8 weeks after DMM surgery, using the Osteoarthritis Research Society International (OARSI) 
scoring system. Values are the mean of standard deviation (SD) of 5 mice per group. P value 
determined by student T-test shows significant degradation in operated knee joints. 
3.3 Discussion 
The rational to generate this mouse line was to develop an effective inducible 
Cre/Lox system to target articular cartilage, and monitor its expression in real-
time. One of the advantages of the inducible system is to circumvent potential 
lethality and skeletal defects during development of cartilage. 
At the time I started my PhD there were already a number of cartilage-specific 
Cre mice. Most of them relied on Col2a1 promoter to deliver the Cre 
recombinase in chondrocytes. Both Ovchinnikov (2000) and Sakai (2001) 
employed DNA sequences of the Col2a1 promoter/first intron to deliver Cre 
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recombinase in cartilage. Both manuscripts demonstrate cartilage-specific 
recombination in embryos, as shown by β–galactosidase activity. In both models 
Cre recombinase expression was detected as early as 9.0 dpc, matching previous 
finding by Zhao in 1997, which investigated Col2a1 expression by in situ 
hybridization. Sakai however observed β–galactosidase activity in osteoblasts, 
speculating that this may be explained by the common progenitor that osteoblast 
and chondrocytes share. Both Ovchinnikov’ and Sakai’s groups did not shown 
data on Cre-mediated recombination in adult mice. In 2007 and 2008 Di Chen’s 
group described a mouse model where the inducible CreERT2 protein was 
expressed in cartilage, driven by a 1kb DNA sequence of the Col2a1 promoter 
(Chen 2007, Zhou 2008). This Cre deleter mouse line was efficient to achieve 
recombination in both embryos and young adult mice (up to 8 weeks of age). The 
authors observed that the percentage of X-Gal-positive articular chondrocytes 
was similar at 1 and 6 months after tamoxifen induction, suggesting that it may 
be due by the minimal turnover in articular cartilage, consistent with the limited 
reparative potential of this tissue. At about the same time the first Aggrecan-
driven CreERT2 mouse line was described by Henry, here he generated a mouse 
by targeted homologous recombination knocking-in the inducible Cre 
recombinase CreERT2, in the 3’ untransated region of the endogenous mouse 
Aggrecan gene. From the data shown in the manuscript, recombination is 
achieved both in embryo and in adult. In adult mice X-gal staining was clearly 
visible in articular cartilage, as well as menisci and growth plate, intervertebral 
discs and annulus fibrosis. 
In this Chapter I demonstrate the generation of inducible Cre deleter where high 
and cartilage-specific expression is driven by Aggrecan enhancer. This was 
illustrated in the double transgenic Aggrecan Cre ERT2 /Rosa26–lacZ reporter. 
When tamoxifen is injected IP to pregnant mother or adult mice, the tamoxifen 
induces the translocation of the Cre recombinase to the nucleus allowing it to 
recombine floxed sequences of DNA, in this case the transcriptional STOP that 
precedes the β-galactosidase gene in the ROSA26 locus (Grover and Roughley 
2006).  This β-galactosidase activity was visualised by X-gal staining of tissues 
during development and postnatally. As with previous aggrecan-driven constructs 
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reported in the literature, including the knock in mouse Agc1(tm(IRES-
creERT2)), where the expression of the Cre recombinase is driven by the 
endogenous gene (Henry, Jang et al. 2009). The expression pattern of our 
transgenic was similar to the endogenous Cre deleter in developing embryos, and 
in adult tissues where expression was evident in cartilagenous tissues, including 
growth plate chondrocytes, articular cartilage, and fibrocartilage cells of the 
meniscus and of the intervertebral disks. Like the knock-in mouse 
Agc1(tm(IRES-creERT2)), I did not observed any staining in brain or the brain 
envelop, nor did I find consistent staining in tendons.  
The unique feature of this mouse is that it is the first Acan-driven transgenic line 
that allows in vivo visualization of Acan gene transcriptional activity in real-time.  
Aggrecan expression has been studied previously. Chambers and colleagues 
(Chambers, Kuffner et al. 2002) investigated by in situ hybridization, the 
expression of both Col2a1 and Acan in young (below 9 weeks of age) and adult 
(above 36 weeks of age) CBA mice. They could not detect differences in the 
distribution of transcripts for Acan and Co2a1 in articular cartilages from young 
mice. However while Acan expression was maintained in adults mice unchanged, 
the Col2a1 mRNA signal was undetectable. These previously findings support 
my observation of stable luciferase expression in mice adult mice up to 16 weeks 
of age. 
Although I do not know whether the level of this transgene is equivalent to the 
endogenous gene, it appear to be expressed under the same conditions as the 
endogenous aggrecan gene, and thus could be used to provide insights on 
changes in endogenous Acan gene as a read-out of druggable target gene 
expression that increase Acan transcriptional activity in osteoarthritis.  
I tested the bioluminescence of this mouse using the surgical model of 
osteoarthritis, on the assumption that as the medial plateau of the operated knee 
joint is degraded during the progression of the disease, I may be able to detect 
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changes in the luciferase transgene, as a reflection of endogenous Acan gene 
expression.  
Our bioluminescence results indicated that the transgene level between the 
operated and non-operated knee remained the same, suggesting that transcription 
of Acan gene did not change in operated knee at any time up to eight weeks 
following surgery. The histological data, however, showed discernable 
anatomical differences on the surfaces of the articular cartilage of the operated 
knee in both the tibial plateau and femoral condyle. This change was significant 
when eight consecutive slides were scored between the operated and un-operated 
knee. This discrepancy between the bioluminescence data and the histology may 
be explained by the inability to distinguish between the luciferase expression in 
articular cartilage versus the growth plate because the resolution of the Kodak 
machine used could not separate one from the other due to close proximity and 
the scatter of the light signal from the tissue. It can be argued that if the luciferase 
signal is far stronger in the growth plate cartilage than that from the articular 
cartilage, it may be impossible to detect change in luciferase signals in the 
articular cartilage of the operated knee. Quantitative PCR analysis on mRNA 
extracted from articular cartilage confirmed stable expression of Aggrecan in 
operated articular cartilage. Being qPCR by far more sensitive that 
bioluminescence, although is an in vitro technique, provide additional strength on 
the in vivo tracking of the gene expression. However it is important to stress that 
stability in Aggrecan expression is contextual to loss of aggrecan protein from the 
articular cartilage. A possible explanation is that although the cartilage ECM is 
affected by surgery, chondrocytes are still alive and maintain the expression 
levels of matrix proteins such Aggrecan.  
It has been already demonstrated that Aggrecan is expressed at detectable levels 
in tissues other that cartilage such as brain. My main interest was to generate a 
cartilage-specific Cre deleter, and I did not investigated expression in other 
tissues. However research focused in brain and neurodegenerative disease is an 
expanding field, and this mouse model may provide useful insight on the 
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expression of Aggrecan in brain cells. Detecting the bioluminescence signal from 
brain or other tissues in vivo may prove difficult for technical reasons such 
distance from the detecting surface of the machine or external tissues shielding 
the signal. However organs could be rapidly dissected and observed. Also cells 
could be isolated and cultured before detection of luminescence. Western blot 
analysis on aggrecan is usually difficult due to the strong interactions between 
matrix proteins, lucifrarese however would be easier to detect and indirectly 
shown if a tissue or cell type express Aggrecan. 
Here I investigated if Aggrecan enhancer elements previously studied by 
Veronique Lefebvre’s group could be suitable to deliver target proteins in 
articular cartilage. Compared to previous reported mouse models, the one I 
generated has expression localization and recombinase activity very similar to the 
one generated by Henry, very likely because both models use aggrecan-driven 
expression. In both β-galactosidase expression is strongly visible in adults mice 
in both articular cartilage and intervertebral discs, as well as menisci and other 
structures such annulus fibrosus. As a direct comparison of expression levels of 
the Cre recombinase cannot be performed, the two models could be comparable 
as cartilage specific deleter. Although my model may seams redundant it offers a 
clear novelty: it allows tracking in vivo of Aggrecan expression, and could be 
employed in other research fields to investigate the involvement of this gene in 
other tissues. 
 According to my aim, I generated a Cre deleter inducible mouse that could be 
useful in studies aimed to better understanding cartilage pathologies such as 
osteoarthritis. I have demonstrated that the vector designed is able to express Cre 
recombinase even in its episomal form, when transfected in mouse embryonic 
cells isolated from ROSA26 Reporter mice. I have also demonstrated that 
transgenic mice generated from this DNA construct, upon tamoxifen induction, 
express both the transgenes either in embryos than in adult. Finally I have shown 
that such expression is stable during the adult life of animals. Taken together 
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those data demonstrate that the transgenic mouse generated is suitable for studies 
focused on the articular cartilage. 
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Chapter 4  
Design and Generation of an 
inducible aggrecan-driven TIMP-3 
and 
[-1Ala]TIMP-3 transgenic mice 
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4.1 Background 
The major threat to the cartilage matrix and thus to the integrity of articular 
cartilage are matrix-degrading enzymes destroying the collagen and proteoglycan 
meshwork. To date, our knowledge focuses mostly on degradation processes of 
collagen type II and aggrecan. Loss of aggrecan is characteristic of the early 
stages of cartilage degeneration, whereas the overall content of collagen remains 
rather constant nearly throughout the disease process. Still, weakening of the 
collagen network is a major feature also in early cartilage degeneration. So far, it 
is unknown what happens first, the loss of proteoglycans or the loosening of the 
collagen network, because both do eventually influence the other. Enhanced 
levels of many MMPs (matrix metalloproteinases), as well as ADAMs (a 
disintegrin and metalloproteinase domain) and ADAMTSs (a disintegrin and 
metalloproteinase domain with thrombospondin type-1 motifs) are the most 
likely candidate enzymes responsible for the increased matrix degradation in OA 
cartilage (Burrage and Brinckerhoff 2007). To date is still unknown which 
proteinasess are really crucial for the degradation of the various cartilage matrix 
components, although MMP-13 is certainly a top candidate for primary collagen 
type II fibril degradation, MMP-2 (gelatinase A) is a good candidate for 
subsequent cleavage of denatured collagen fibrils (gelatins), whereas ADAMTS-
4 and ADAMTS-5 are favored to be the major aggrecanases responsible for the 
aggrecan breakdown. This lack of knowledge is particularly striking considering 
that the incidence and prevalence of osteoarthritis will continue to rise because 
the general aging of the population, and unless measures are taken to improve 
disease prevention and/or cure, Based on current trends, osteoarthritis is forecast 
to become the fourth leading cause of disability worldwide by the year 2020 
(Woolf and Pfleger 2003). 
So far several broad range inhibitory molecules were tested for osteoarthritis 
treatment. A whole class of them was designed to target MMPs, but the clinical 
development of broad-spectrum synthetic inhibitors has been hampered by 
adverse events, in particular the pain associated with joint ﬁbroplasia in the 
musculoskeletal syndrome (MSS) (Renkiewicz, Qiu et al. 2003). 
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All the aforementioned enzymes are regulated, in physiological conditions, by the 
Tissue Inhibitors of MetalloProteinasess (TIMPs). Interest in the research group 
led by my supervisor Dr George Bou-Gharios in collaboration with Prof Hideaki 
Nagase focused on the use of these endogenous inhibitors and specifically the 
TIMP-3 protein and its synthetic mutant [-1Ala]TIMP-3 as potential treatments 
of osteoarthritis. TIMP-3 was shown to be a major regulator of MMPs and 
ADAMTSs and mice lacking their homologous protein seem to face age-related 
increase in collagen and aggregan degradation (Sahebjam, Khokha et al. 2007). 
Previous studies have shown that in vitro [-1Ala]TIMP-3 could block only 
aggrecanases (ADAMTS-4 and -5) and ADAMs (TACE/ADAM-10) (Lim, 
Kashiwagi et al. 2010). As mentioned in the Introduction chapter, ADAMTS-5 
has been shown to be one of the enzymes mostly responsible for cartilage 
degradation in mice because mice deﬁcient in ADAMTS-5 (but not ADAMTS-4) 
are protected from early aggrecan loss and cartilage erosion in a surgically-
induced model of osteoarthritis (Glasson, Askew et al. 2005).  
I decided to test in vivo the potential role of TIMPs in treatment of osteoarthritis 
and to generate transgenic mice that overexpress those proteins.  
My aim was to generate a conditional/inducible cartilage-specific transgenic 
mouse in which TIMPs can be over-expressed at any given time in adult mice, 
such as before DMM surgery (Glasson, Blanchet et al. 2007). It was of 
paramount importance to use a promoter that would drive cartilage-specific 
expression throughout adulthood, as osteoarthritis is a late-onset disease. I 
demonstrated my own Cre deleter mouse strain (Chapter 3) was sufficient to 
drive the expression in cartilaginous tissues, I decided to use the same elements 
to generate the TIMP-expressing conditional mice.  
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4.2 Results 
4.2.1 Design and construction of expression vectors 
The DNA construct was designed to harbour the aggrecan regulatory elements, a 
floxed transcriptional STOP, the human TIMP-3 (or its mutant) coding sequence, 
an IRES, the E.coli lacZ gene and the SV40 (Simian Virus-40) polyadenylation 
(polyA) sequence. Both TIMP-3 and its synthetic mutant were FLAG tagged at 
the C-terminal, while the lacZ gene was modified to have a nuclear localization 
sequence (nls) that allows the protein to translocate and be retained into the 
nucleus. Protein tagging has been used widely in many research filed to help 
detect proteins of interest because the lack of strong antibody against the protein 
target as well as because of specific techniques such as protein purification or 
immunoprecipitation. FLAG system utilizes a short, hydrophilic 8-amino acid 
peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) that is fused to the recombinant 
protein of interest when expressed from a pFLAG vector (Terpe 2003, Brizzard 
2008). FLAG tag's structure has been optimized to be more hydrophilic than 
other common epitope tags, therefore is more likely to be located on the surface 
of a fusion protein and less likely to denature or inactivate proteins to which it is 
appended. Finally because of the small size of the FLAG peptide tag, it is not 
likely to obscure other epitopes, domains, or alter function, secretion, or transport 
of the fusion protein. In addition, N-terminal FLAG tags can be removed readily 
from proteins once they have been isolated, by treatment with the specific 
protease, enterokinase. Many papers had shown that FLAG tag does not 
influence the target protein and specifically published and unpublished works in 
our lab shown that it does not affect the TIMPs activity in vitro (Troeberg, 
Fushimi et al. 2009, Scilabra, Troeberg et al. 2013). The structure of the vector is 
schematized in Figure 4.1 (up). TIMP-3-Flag sequence was present in the Matrix 
Laboratory archive at KIR. The sequence was lifted from an original plasmid 
construct and cloned in a pIRES plasmid (originally from Clontech Laboratories) 
harbouring the LacZ gene downstream to the IRES sequence (also present in the 
same archive). The TIMP-3-Flag/IRES/LacZ was then lifted and cloned in 
downstream to Aggrecan enhancer sequences. Two constructs were generated to 
express either the TIMP-3 and its synthetic mutant [-1Ala]TIMP-3. These 
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constructs cannot constitutively express the transgenes because the presence of 
the transcriptional STOP, made by several repeated sequences of polyA. The 
loxP sites that flank the transcriptional STOP are recognized by the Cre 
recombinase from the P1 Bacteriophage. The loxP sites are 34 bp-long and 
consist of two 13 bp palindromic sequences that flank an 8bp spacer region. The 
Cre recombinase, a 38 kDa enzyme and member of the integrase family, 
catalyzes a site-specific recombination via a topoisomerase I-like mechanism 
(Figure 4.1, down). The outcome of the Cre-mediated recombination is 
dependent upon the location and relative orientation of the loxP sites. 
Recombination could occur between two different DNA species if located close 
enough. Interesting DNA found between two loxP sites oriented in the same 
direction will be excised as a circular loop of DNA whilst DNA between two 
loxP sites that are opposing-orientated will be inverted. 
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Figure 4.1: Schematic diagram of the Col2-4xA1-TIMP-3 IRES nlacZ plasmid and its 
mechanism. It consists of a Col2a1 minimal promoter (Col2) plus four tandem repeats of mouse 
Aggrecan enhancer A1; transcriptional STOP sequences flanked by loxP sites; C-term flagged 
hTIMP-3 coding sequence; IRES; E.coli lacZ gene conatining a nuclear localization sequence; 
polyA sequence. After Cre-mediated intrachromosomal recombination, the STOP sequence is 
excised allowing the expression of both of the downstream genes as a single mRNA. Arrows 
denote the direction of transcription. E.coli origin of replication and ampicillin resistance gene are 
not shown. IRES: internal ribosome entry site; polyA: polyadenylation sequence; E.coli origin of 
replication and Ampicillin resistance gene are not shown. 
The original Col2a1-4xA1-CreERT2 plasmid was digested with BglII/SapI 
restriction enzymes, in order to isolate the aggrecan regulatory elements. This 
DNA fragment of 5kb also contained the origin of replication site, and it was 
handled as the vector fragment (Figure 4.2 A, left). The TIMP-3 coding 
sequence, the IRES and the lacZ gene together were isolated from a plasmid 
previously generated in our group using the EcoNI/AscI restriction enzymes. 
This DNA fragment was handled as the insert fragment (Figure 4.2 A, right). 
Both vector and insert were subjected to treatment with the Klenow enzyme, that 
has a 5'-3' polymerase activity, in order to make 5' overhang extremities blunt. 
Vector fragment was also treated with Calf Intestine Phosphatase (CIP), which 
catalyzes the removal phosphate groups at the 5’ termini, reducing the ability of 
the vector fragment to self-ligate. The vector and insert fragments were ligated 
together using the T4 ligase enzyme. Digestion with XmnI restriction enzyme 
produced the expected digestion fragments (Figure 4.2 B). The plasmids 
generated as described were named LLC1 Col2-4xA1 hTIMP-3 IRES nlacZ 
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(LLC1 in short) and LLC2 Col2-4xA1 [-1Ala]hTIMP-3 IRES nlacZ (LLC2 in 
short). Both vectors were sequenced in order to confirm the sequences of the 
backbone and discriminate between the coding sequences of the two genes 
(Figure 4.2 C). 
Figure 4.2: Cloning strategy used to generate the Col2-4xA1-TIMP-3 IRES nlacZ. A: 
Col2a1-4xA1-CreERT2 plasmid was digested with SapI/BglII restriction enzymes, to isolate the 
aggrecan elements in the 5 kb fragment (left); A plasmid containing hTIMP-3-Flag coding 
sequence was digested with EcoNI/AscI restriction enzymes, to lift the hTIMP-3-F IRES lacZ 
sequence in the 7,2 kb fragment (right). B: LLC1 and LLC2 plasmid were digested with XmnI 
restriction enzyme in order to confirm the correct direction of the ligation: three fragments were 
expected: 5.7 kb, 3.9 kb and 2.6 kb. C: LLC1 (above) and LLC2 (below) plasmids were 
sequenced in order to confirm the presence of the extra Alanine in position -1. 
The first question that I wanted to answer was wheter the plasmids were able to 
express the reporter gene in mammalian HTB94 chondrosarcoma cells. These 
cells were transfected using the Invitrogen Neon System (electroporation). 
Cultured cells were counted and re-suspended in a proprietary buffer. 1.0 x 106 
cells were transiently transfected with 30 μg of the chosen vector and seeded in 
two 6 cm of diameter culture dishes, in whole growing media and allowed to rest 
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24 h. In order to activate the transgene expression, the transcriptional STOP has 
to be removed by the Cre recombinase enzyme. Transfected cells were than 
transduced with an adenovirus expressing a Cre recombinase featuring a NLS, 
therefore not dependent on tamoxifen administration. Cells were incubated for 48 
h and were stained for X-gal in order to evaluate the result of the experiment. I 
have optimized the infection procedure using MEF (mouse epithelial fibroblast) 
isolated from Rosa26 Reporter mice (Grover and Roughley 2006).  In optimizing 
the adenovirus transduction my main concern was on cell viability. I arbitrary 
selected 4 different MOIs (10, 25, 50, 100) and infected MEF cells isolated from 
Rosa26 Reporter embryos. The number of positive cells was increasing up to 50 
MOI, but not much between 50 and 100 MOI. However I could observe several 
floating cells when the highest MOI was used, thus I decided to use 50 MOI that 
provide by observation the highest result with least side effect. I used as negative 
controls MEF from WT embryos treated with virus and MEF from Rosa26R not 
treated with virus.  
Interestingly, although cells looked healthy, and the same experiment was 
repeated several times, the observed amount of cells which stained in blue after 
transfection and transduction, was quite low (Figure 4.3 A,B). Transfection of 
different DNA constructs of similar size but driven by different promoter, 
however shown a higher number of stained cells (Figure 4.3 C). A possible 
explanation could be the episomal structure of the plasmid, that might make it 
more difficult for the enhancer to induce the genes, or a combination of this event 
plus the recombination event driven by the Cre recombinase. Because TIMP-3 is 
an extracellular protein, I tried to detect it in the conditioned media by western 
blot analysis. Troeberg and Scilabra demonstrated that TIMP-3 is actively 
internalized, however that process could be mostly inhibited by adding heparin to 
the growth media (Scilabra, Troeberg et al. 2013). Experimental evidences 
demonstrated no appreciable difference in the TIMP-3 amount between LLC1- or 
LLC2-transfected and mock-transfected cells. 
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Figure 4.3: Representative bright field images of HTB94 cells transfected with the aggrecan-
driven plasmid. HTB94 cells were transfected with an target plasmid using the Neon 
electroporation system (Invitrogen) e 24 hours later were transduced with a CMV-driven 
adenovirus expressing nCre recombinase. After 48 hours cells were fixed and stained for X-gal. 
A-B: Random fields from two independent experiments of LLC1 transfected cells.  C: Random 
field from a control experiment using a general promoter. 
4.2.2 Generation of transgenic mice 
I decided to use both LLC1 and LLC2 plasmid to generate transgenic mice. Dr 
Ke Liu performed the whole procedure in the KIR animal facility. Both LLC1 
and LLC2 plasmid were linearized by digestion with NaeI/SphI restriction 
enzymes, obtaining a 10 kb fragment.  Linearization allowed removing the region 
of the vector backbone containing both the E.coli origin of replication and the 
ampicillin resistance gene. As described in Chapter 2 linearized vectors were 
injected in the male pronucleus of fertilized oocyte to generate the transgenic 
mice. When microinjected into pronuclei, transgenes are integrated at random 
into the genome. Thus, each founder will have a different site(s) of integration. 
The number of copies of the transgene possessed by each founder may also be 
different and there may be more than one site of integration within the genome. 
For all these reasons, each founder should be treated as a separate line and bred 
independently of other founders carrying the same transgene.  Offspring obtained 
from each founder is required to be tested for transmission and expression of the 
transgene. Due to position effects and different copy numbers, each founder line 
can have a different level of expression. A percentage of positive founders of 
11,68 % (7 of 60) and 8,16 % (4 of 49) for LLC1 and LLC2 constructs, was 
obtained respectively. 
Once the mouse lines were established I wanted to evaluate the expression of the 
reporter gene, thus founder mice were mated to Cre recombinase expressing mice 
(ROSA-Cre, B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J mice, The Jackson Laboratory, 
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USA). Pregnant mothers were injected with 5 mg of tamoxifen 14 days after 
mating (E14.5). These mothers were sacrificed at E15.5 and the embryos were 
fixed and stained with X-gal. If blue staining was evident and uniform in 
cartilaginous structures, the transgenic line was maintained. I identified two 
transgenic lines for the LLC1 construct (lines 53 and 58) and two lines for the 
LLC2 (lines 18 and 47). Transgenic line LLC2.47 was discarded afterwards 
because expression levels were not judged sufficient to deliver the transgene 
(Figure 4.6 J). All the founders were bred for homozygous lines. At the same 
time transgenic mice were crossed to homozygous ROSA-Cre mice to obtain 
double transgenic adult mice. The transgenic mouse lines used for breading were 
heterozygous and only after few generations I obtained homozygous mice. Using 
heterozygous in the ROSA-Cre breeding led to a progeny positive of only on 
50% for the Cre recombinase. 
I compared the different lines in order to evaluate if the staining was uniform 
among the transgenic lines and eventually comparable. Particular attention was 
paid to the patterning of the staining. Because transgenic mice are generated by 
pronuclear microinjection, as already discussed in the Introduction chapter, 
position variegation effects (PVEs) may occur if vector copies land in compact 
chromatin regions. 
All lines generated from the aggrecan-driven vectors expressed β-galactosidase in 
all the cartilaginous structures of the embryos after tamoxifen administration to 
the pregnant mother. However not all of them were stained similarly. Here I will 
describe the study of the LLC1 #53 mouse line that overall performed best. The 
remaining transgenic lines shown variable results and will require further 
investigation. A strong blue color was observed in the developing cartilage of the 
long bones of the fore and hind limbs, the ribs, the scapulae, the digits and some 
craniofacial cartilages such as olfactory, otic and jaws cartilages. Spine and tail 
were also stained. It was clearly visible the formation of secondary centers of 
ossification in the long bones. Both tibia plateau and femur condyles showed blue 
staining (Figure 4.4).  
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Figure 4.4: Representative E15.5 wholemount embryos expressing β -galactosidase (blue 
staining) driven by the Aggrecan enhancer. A-F: Double transgenic embryos were showing 
identical and symmetrical staining. G: Double transgenic embryos without tamoxifen 
administration did not expressed β-galactosidase. A,D,E,F,G are lateral images while B and C 
are frontal and dorsal images. f (femur), fd (forelimb digits), fi (fibula), h (humerus), hd (hindlimb 
digits), m (Meckel’s cartilage), r (rib cartilage), ra (radius), sc (scapular cartilage), t (tibia), u 
(ulna). 
Furthermore I wanted to know how the β-galactosidase expression was 
distributed among the chondrocytes. Whole embryos were embedded in wax and 
histological sections cut along the sagittal plan. Observation at higher 
magnification showed that the nuclei of all chondrocytes were stained in blue 
(Figure 4.5), and thus were expressing the transgene. 
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Figure 4.5: Representative histological sections of E15.5 double transgenic embryo 
expressing β -galactosidase (blue staining) driven by the Aggrecan enhancer. A-C: 
representative images of shoulder articulation, knee joint and ribs cage, respectively. D-F: higher 
magnification images of A-C. G-I are representative images of scapula, humerus and rib, 
respectively. f (femur), h (humerus), sc (scapular cartilage), t (tibia). 
Because the aim of this particular section was to obtain cartilage-specific 
expression in adult mice, 6 week old double transgenic mice were injected with 
1.5 mg Tamoxifen three times every 48 h. Mice were sacrificed two weeks later 
(8 weeks old) and several tissues harvested. Knee joints were exposed to increase 
penetration of X-gal staining solutions, which was carried out according to the 
protocol (Chapter 2.2, Methods). Whole mount X-gal staining demonstrated that 
expression of the lacZ gene was in hyaline cartilage. As the major aim was to 
express in the knee joint articular cartilage, staining demonstrated both tibia 
plateau and femur condyles from double-transgenic mice were stained blue but 
not the non-double-transgenic littermates (Figure 4.6 A-C). Cartilage 
surrounding the hip was also strongly stained. In double transgenic mice without 
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tamoxifen administration, no x-gal staining was observed in cartilage (Figure 4.6 
D-F). Finally I looked for expression in non-cartilaginous tissues and confirmed 
that the transgene is not expressed outside cartilage (Figure 4.6 G-I). 
Figure 4.6: Representative pictures of adult double transgenic mice expressing β -
galactosidase (blue staining) driven by the Aggrecan enhancer. 8-weeks old double transgenic 
mice and wildtype littermates were injected with Tamoxifen and sacrificed 2 weeks later. Tissues 
were isolated and stained for X-gal. A-I: Line LLC1.53. J: LINE LLC2.47. A-C representative 
images of femur condyles, tibia plateau and hip head from double transgenic transgenic mice; red 
boxes are zoomed particulars. D-F: representative images of femur condyles, tibia plateau and hip 
head from double transgenic mice without tamoxifen administration. G-I: representative images 
of heart, lungs and liver from double transgenic transgenic mice treated with tamoxifen. J: 
Representative image of femur condyles of a double transgenic mice LLC2.47, showing much 
lower staining compared to line LLC1.53. 
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4.2.3 Quantification of the expression levels and detection of TIMP-3 protein in 
adult tissues  
A key question to address was about the TIMP expression levels in those mice. 
Six weeks old double transgenic mice were injected with 1.5 mg tamoxifen IP, 
three times every 48 h. Mice were sacrificed two weeks later (8 weeks old). 
Knees were isolated and cartilage was micro-dissected and stored in RNAlater 
solution. RNA was extracted, purified and reverse transcribed into cDNA, as 
described in the Methods. Micro-dissection of the articular cartilage proved to be 
a challenging method. Articular cartilage is just few tens of micron thick 
(Stockwell 1971) and thus avoiding damage to the underneath bone is very 
difficult. Using a micro-rongeur, allows gently scraping the surface to the joint, 
collecting the overlying articular cartilage. Moreover extracting RNA from the 
dissected cartilage is a very difficult task because the huge amount of charged 
protein of the tissue. The protocol for RNA purification is described in the 
Chapter 2.2. The amount of RNA extracted from the articular cartilage of two 
knee joints was sometime insufficient; nevertheless I decided not to mix 
individual mice, in order to highlight the expected individual variability among 
the same group of transgenic mice. All primers/probe sets for human TIMP3 and 
mouse Hprt were bought from Applied Biosystems. Although the primer set was 
designed for human TIMP3 gene, it was able to detect the endogenous mouse 
gene. The explanation relies on the fact that mouse and human TIMP-3 proteins 
share 95% identity in the aminoacid sequences. Real-time PCR analysis showed 
an increase of the Timp3 expression of ~4 fold. The data were analysed using the 
paired T-test, and proved to be statistically significant (Figure 4.7).  
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Figure 4.7: Timp3 upregulation in double transgenic mice after Tamoxifen administration. 
Real-time PCR analysis of Timp3 in mouse articular cartilage of 10-weeks old double transgenic 
mice and control mice (WT). Tamoxifen was administrated at 8-weeks of age. Y values represent 
fold difference of timp3 expression compared to endogenous Hprt expression. n=3. P < 0.05. 
Error bars represent  (SD). Hprt: hypoxanthine guanine phosphoribosyl transferase. 
The last evidence for the analysis of the transgenic line was to detect the TIMP 
protein in the articular cartilage. Six-weeks old double transgenic mice were 
injected with 1.5 mg Tamoxifen via IP, three times every 48 h. Mice were 
sacrificed two weeks later (8 weeks old). Knees were isolated fixed in neutral 
buffered formalin 10% for 24 h and decalcified in 10% EDTA pH 7.4 for 4-5 
weeks. Subsequently tissues were embedded in paraffin and sectioned. As 
previously stated RNA extraction, the main difficulty in cartilage work is given 
by the high amount of charged proteins in the ECM. To detect the TIMP-3 
protein by immunofluorescence, the ECM was partially digested by 
hyaluronidase treatment. The concentration of anti-TIMP-3 antibody was 
optimized to reduce the tissue background signal, so that it was very low, 
although not completely absent, in sections samples from TIMP3-KO mice. The 
fluorescence signal was observed in the chondrocytes pericellular space 
transgenic mice, but not in wild type littermate (Figure 4.8). 
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Figure 4.8: Representative confocal images of coronal histological sections from knee joint 
from 10-weeks old mice. 8-weeks old double transgenic mice and wildtype littermates were 
injected with Tamoxifen and sacrificed 2 weeks later. Knee tissues were isolated and after 
decalcification embedded in wax. Increase in TIMP-3 (green) was observed in double-transgenic 
mice tissues (A,D) but not in wildtype littermates (B,E). Very low background signal was 
detected in tissues from TIMP-3 KO mice (C,F). A-C are representative images for femur 
condyles, D-E for tibia plateau. Tissues were counter stained with DAPI to highlight cells nuclei. 
4.3 Discussion 
In this chapter I described all the steps undertaken to generate an inducible 
transgenic mouse that express TIMP-3 specifically into the articular cartilage. I 
generated several transgenic lines that express either human TIMP-3 or [-
1Ala]TIMP-3, and selected the most promising ones in terms of expression levels 
and localization.  
Because of their role in cartilage remodelling, both metalloproteinases and 
aggrecanases were targeted in clinical trials for treatment of osteoarthritis. 
Several synthetic inhibitors were designed and tested, but data have shown that 
such inhibitors may produce musculoskeletal side effects characterized by joint 
stiffness, joint fibroplasias and accumulation of type I collagen in the affected 
joints (Renkiewicz, Qiu et al. 2003). Possible reasons could be the low selectivity 
of the inhibitors, this data are pushing research groups to develop selective 
inhibitors of proteinases rather than broad proteinases inhibition. 
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I selected TIMP-3 as possible target for osteoarthritis treatment because it 
regulates the pro-MMP-2 activation and demonstrates high affinity inhibition of 
both ADAMTS-4 and ADAMTS-5. Moreover knowing that its broad activity 
towards most of MMPs and aggrecanases could results in a less clear phenotype, 
I decided to take advantage of synthetic mutant of TIMP-3 that were generated 
and studied in Gill Murphy‘s research groups (Lee, Verma et al. 2002). 
Particularly the [-1Ala]TIMP-3 was shown to be able to inhibit in vitro 
aggrecanases and TACE enzymes, but not MMPs (Lim, Kashiwagi et al. 2010). 
I decided to generate a transgenic mouse that could express TIMP-3 specifically 
in the cartilage tissue, in order to minimize the effects of expression from other 
tissues such as subchondral bone, or synovial tissue. I take advantage of the Cre 
deleter described in the previous Chapter, and generated two plasmids named 
LLC1 and LLC2, that could express TIMP-3 and  [-1Ala]TIMP-3 respectively. I 
tested if the plasmids could express the transgene or the reporter gene (lacZ) in 
vitro, transfecting HTB94 (chondrosarcoma) cells. Because a floxed 
transcriptional STOP region prevented the expression, transfected cells were also 
transduced with an adenovirus expressing the Cre recombinase, to mediate the 
recombination. X-gal staining on those cells showed that E.coli lacZ gene was 
expressed as nuclei were stained of blue. Troeberg and Scilabra in their 
experiments on TIMP-3, succeeded in detecting the protein in the stable 
transfected cell media treated with heparin. They also have shown that TIMP-3 is 
actively removed from the pericellular space by direct endocytosis.  I was not 
able to detect TIMP-3 in transfected cell media, probably because of the low 
amount of protein produced. The discrepancy with the strong blue staining of the 
nuclei could be explained by the fact that the β-galactosidase enzyme is 
accumulated in the nuclei, instead TIMP-3 is degraded once internalized. Both 
the plasmids were used to generate transgenic mice that were mated to a ROSA-
Cre deleter. Mouse lines showing blue staining in the progenies were kept, all the 
rest were cull. Among all the mice obtained I decided to maintain two lines for 
the LLC1 plasmid (#53 and #58) and one for the LLC2 plasmid (#47). Among all 
LLC1 #53 shown best expression patterning, the other lines will require further 
investigation. From whole-mount X-gal staining, expression was evident in all 
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cartilaginous structures. Spine and ribs, jaw and otic cartilage as well as knee and 
elbow were clearly stained. Because these results were promising I decided to 
analyse the adult mice. Whole-mount X-gal staining as well as sagittal sections of 
the knees demonstrated that those mice expressed the lacZ gene also in adult 
tissue. Blue staining was observed in the cartilage surrounding hips, but not in 
other tissues such as liver or kidney. I expected different levels of expression of 
the transgene among the different mouse lines. Such difference could not be 
appreciated in X-gal staining because it is an end-point essay, and measures did 
not correlate with the real values. Transgenic mice expressed about 5 times more 
Timp3 mRNA, after two weeks activation via tamoxifen, compared to the wild-
type ones. TIMP-3 protein localization was investigated by immunofluorescence, 
and I was able to detect an increase in signal in the transgenic mice compared to 
the wild-type ones.  
There is small amount of literature on TIMP-3 mRNA expression in mouse 
embryos. The mayor study on TIMP-3 expression and localization in mouse has 
been conducted by Suneel Apte and colleagues in 1994 (Apte, Hayashi et al. 
1994). Their paper was the first to describe genomic localization and expression 
pattern of TIMP3 in mouse. Northern Blot analysis of mRNA in several mouse 
adult tissues shown that kidney is by far the organ with the highest expression of 
Timp3 transcript, followed by lung, and brain. They also shown that Timp3 
message is highly expressed both in developing and new–born mouse tissues. 
Localization of the Timp3 transcript was observed by in situ hybridization (ISH) 
in both embryo and newborn mice. Expression of Timp3 mRNA was observed in 
E14.5 embryos in Meckel’s cartilage, otic capsule, intervertebral disc and 
hypertrophic chondrocytes of the vertebral cartilage. Timp3 mRNA was also 
observed in intervertebral disc and hypertrophic chondrocytes of the ribs and 
sternum in new-born mice.  In 1997 Chin and Werb performed in situ 
hybridization (ISH) on mouse dissected mandibles from mouse embryos, 
obtaining evidences that TIMP-3 mRNA is expressed intensely in the 
mesenchyme in the pre-osteoid region and along the medial axis of the tongue of 
E12-E14 embryos, but not in Meckel’s cartilage (Chin and Werb 1997). Blavier 
and DeClerk in 1997 investigated the expression of TIMP-3 in adult mouse 
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tissues by Northern Blot: kidney was by far the organ with the highest 
expression, followed by lung (Blavier and DeClerck 1997). Weaker signal was 
detected also in brain, eye, heart and ovary. Although I did not performed any 
ISH studies, from the β-galactosidase staining pattern seams evident that in my 
model TIMP-3 could be expressed in different tissues in respect of wild-type, and 
this support furthermore my choice to generate and inducible model where 
TIMP-3 expression does not affect the physiological expression pattern during 
early and late embryogenesis and early development. 
Taken together all those data prove that the approach I pursued was right and I 
can deliver exogenous TIMP-3 in mouse knee articular chondrocytes. Because 
there is not literature on this specific field I did not knew if such increase will be 
sufficient to produce a phenotype in OA-induced animal. I do know that TIMP-3 
is physiologically regulated not just at the transcription level, but it is actively 
endocytosed via more than one pathway (Scilabra, Troeberg et al. 2013). Among 
the transgenic mouse lines generated so far, I foresee that line LLC1 #53, is a 
good candidate to undergo further studies and investigate the potential role of 
TIMPs overexpression in osteoarthritis. 
 Chapter 5  
Design and Generation of an 
inducible Ubiquitin C-driven TIMP-3 
and  
[-1Ala]TIMP-3 transgenic mice 
Leandro Lo Cascio  PhD Thesis 
 116 
5.1 Background 
As previously stated the major aim I tried to fulfil was to generate an inducible 
system specific for mouse articular cartilage transgenic expression. However I 
was well aware that in the content of the knee joint, articular cartilage is not the 
only tissue responsible of the maintenance of the joint physiology. Although 
articular cartilage is the main tissue affected during early stage OA, the 
subchondral bone region underneath influences and is influenced in turn, not only 
by mechanical effects, but also by exchange of catabolic factors. In vivo 
observations in human OA patients demonstrates interdependence between the 
loss of cartilage and the deterioration of the subchondral bone structure (Sharif, 
George et al. 1995, Wildi, Raynauld et al. 2010). Emerging evidence suggests 
that very early in the OA process, biological and morphological disturbances 
occur at the subchondral bone level that play a role in modulating articular 
cartilage metabolism. 
In OA, the role of synovial inflammation in the pathophysiology of OA is now 
widely accepted. Synovitis has been considered secondary to the cartilage 
changes yet findings indicate that synovial inflammation could be a component 
of the early events leading to the clinical stage of OA. Synovial inflammation 
leads to the production and release of pro-inflammatory cytokines and several 
other inflammatory mediators. Some of these factors, including the pro-
inflammatory cytokines, diffuse through the synovial fluid into the cartilage, 
where they activate chondrocyte production of the catabolic factors through auto- 
and paracrine mechanisms. 
This evidence led me to design a second strategy of transgene delivering using a 
ubiquitous promoter in order to deliver the transgene in other tissues. A 
peculiarity of ubiquitous promoters is that they are expressed in virtually all cells 
of the organism because they usually belong to those genes responsible for 
important cell processes that are little altered by external stimuli. One of the most 
common system to express a transgene is the cytomegalovirus (CMV) enhancer/ 
chicken β-actin promoter (CAG) (Niwa, Yamamura et al. 1991). Another 
example is the human promoter of the ubiquitin C, as was shown by Schorpp, it 
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is able to drive expression of target genes both in vitro and in vivo (Schorpp, 
Jager et al. 1996). 
5.2 Results 
5.2.1 Design and construction of expression vectors 
The expression vector containing the human Ubiquitin promoter was kindly 
donated by Richard Behringer’s group, and is described in Stewart et al. (Stewart, 
Jang et al. 2009) (Figure 5.1 A). Here the human Ubiquitin C (UBC) promoter 
fragment was used to direct expression of the HS-GR cassette (UBC-HS-GR) in a 
wide variety of embryonic cell types (Schorpp, Jager et al. 1996). To reduce 
position effects at the site of transgene integration, the transgene was flanked by 
two copies of cHS4 (chicken hypersensitive site 4) transcriptional insulators 
(Potts, Tucker et al. 2000).  
I designed a three-steps plan to construct the final vector (Figure 5.1 B). 
- I first lifted the whole “STOP-TIMP3-IRES-LacZ-polyA” sequence from 
the Col2-4xA1 hTIMP-3 IRES nLacZ described in Chapter 4. 
- I than digested the UBC-HS-GR expression vector from Stewart, 
removing all sequence in between the UbC promoter and the cHS4 site.  
- Finally I ligated the “STOP-TIMP3-IRES-LacZ” sequence into the empty 
UbC-driven vector. 
The final construct was named UbiquitinC hTIMP-3 IRES nLacZ. 
The expression vector designed for expression of TIMP-3 is schematized in 
Figure 5.1. Similarly to the plasmid described in Chapter 4, here the human 
TIMP-3 coding sequence is linked to the lacZ gene by an IRES sequence. The 
lacZ gene, modified with a nuclear localizing sequence is followed by a 
polyadenylation sequence (polyA) to allow expression in eukaryotic cells. The 
expression vector harbours two tandem repeats of the chicken β-globin 
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hypersensitive site 4 (cHS4) that have been shown to function as transcriptional 
insulators, thus increase shielding of transgenes from position effects in cell-lines 
and transgenic mice (Potts, Tucker et al. 2000). Expression is driven by the 
Ubiquitin C promoter/first intron. The expression vectors were generated 
similarly to the aggrecan-driven ones, and named Ubiquitin C hTIMP-3 IRES 
nlacZ (UbCT3 in short) and Ubiquitin C [-1Ala]hTIMP-3 IRES nlacZ (UbCAla 
in short). As for the Aggrecan-driven expression vectors, in order for these 
constructs to express the transgenes, a recombination event mediated by the Cre 
recombinase is required because of a floxed transcriptional STOP. 
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Figure 5.1: Schematic diagram of the UbC-TIMP-3 IRES nlacZ expression vector. It consists 
of a Ubiquitin C minimal promoter/first intron to drive expression; transcriptional STOP 
sequences flanked by loxP sites; C-term flagged hTIMP-3 CDS; IRES; E.coli lacZ gene plus 
NLS; polyA sequence; cHS4 chicken hypersensitive site 4. After Cre-mediated intrachromosomal 
recombination, STOP sequence is excised allowing the expression of both of the downstream 
genes as a single mRNA. Arrows denote the direction of transcription. E.coli origin of replication 
and ampicillin resistance gene are not shown. IRES: internal ribosome entry site; polyA: 
polyadenylation sequence. 
The first question that I wanted to answer was if the plasmids were able to 
express the reporter gene in mammalian HTB94 chondrosarcoma cells. Those 
cells were transfected using the Neon System (Invitrogen) as described in the 
Methods chapter. In brief cultured cells were counted and resuspended in a 
proprietary buffer and 1.0x106 cells were transiently transfected with 30mg of the 
chosen vector and seeded in	 two	 6	 cm	 of	 diameter	 culture	 dishes,	 in	 complete	
medium	and	incubated	for	24	h. In order to activate the transgene expression, the 
transcriptional STOP has to be removed by the Cre recombinase enzyme. 
Transfected cells were than transduced with a CMV-driven adenovirus 
expressing the Cre recombinase enzyme modified with a nuclear localizing 
sequence, therefore not dependent on tamoxifen administration for relocating in 
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the nucleus. Cells were incubated 48 h and tested for lacZ	expression.	As	expected	
the	UbC-driven	 vectors	 generated	were	 able	 to express β-galactosidase protein in 
very high levels (Figure 5.2). Particularly striking was the number of stained 
cells compared to the Aggrecan-driven vector. Based on these evidences I 
decided to generate transgenic mice from these expression vectors. 
Figure 5.2: Representative bright field images of HTB94 cells transfected with the Ubiquitin 
C-driven plasmid. HTB94 cells were transfected with an target plasmid using the Neon 
electroporation system (Invitrogen). 24 hours later cells were transduced with a CMV-driven 
adenovirus expressing nCre recombinase. After 48 hours cells were fixed and stained for X-gal. 
A-D: Random fields from four independent experiments. 
5.2.2 Generation of transgenic mice 
Both UbC-TIMP-3 and UbC-1AlaTIMP-3 vectors were linearized after digestion 
to remove part of the plasmid backbone containing both the origin of replication 
and the ampicillin-resistance gene. As previously described Dr Ke injected the 
linearized DNA in the male pronuclei of fertilized oocytes, which were than 
transferred in surrogate mothers (C57BL/6 background). Progeny was screened 
by PCR for the lacZ gene	to	identify	the	positive	transgenics. 
Transgenic mice, identified by PCR, were mated to ROSA-CreRT2 mice in order 
to obtain double transgenic animals. Pregnant female were injected once with 5 
mg of tamoxifen at embryonic day E14.5 and sacrificed the day after. Embryos 
were collected and stained for β-galactosidase. As expected I observed variability 
in β-galactosidase staining and the least promising transgenic mouse lines were 
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culled. Transgenic line UbCAla #38 proved to be the most promising line, so I 
will describe the characterization of this particular line. 
The use of a non-tissue specific promoter allowed the transgene to be expressed 
in most of the mouse tissues. Embryos were found positive for X-gal staining in 
skin, cartilage, and some internal organs (Figure 5.3). 
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Figure 5.3: Representative E15.5 wholemount embryos expressing β-galactosidase (blue 
staining) driven by the UbiquitinC promoter. A-E: Images from a double transgenic embryo 
after tamoxifen administration. F: Representative double transgenic embryo without tamoxifen 
administration. Transgenic mice shown identical and symmetrical staining. Compared to the 
Aggrecan-driven construct were only cartilage was stained, here the staining appears diffused. 
To evaluate localization and levels of lacZ expression in adult tissues 8-week-old 
double transgenic mice were injected 3 times every other day 1.5 mg of 
tamoxifen and sacrificed 2 week later. Several tissues were collected and stained 
for X-gal. Strong blue staining was observed in the articular cartilage of tibias, 
femurs and hips. Some X-gal positive staining was observed also in ribs, and 
tendons. However no staining was observed in heart or lung (Figure 5.4). 
Staining in the heart was expected as Stewart and colleagues in their 2009 paper 
have shown that a similar construct is able to delivery eGFP in the heart of E11.5 
mouse embryos (Stewart, Jang et al. 2009). Further investigation has to be done 
to address this discrepancy, although it may diverge from the target of the present 
work.  
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Figure 5.4: Representative pictures of adult double transgenic mice expressing β -
galactosidase (blue staining) driven by the Ubiquitin C promoter. 8-weeks old double 
transgenic mice were injected with Tamoxifen and sacrificed 2 weeks later. Tissues were isolated 
and stained for X-gal. A-D strong staining was observed in both femur condyles and tibia plateau 
as well as rib cage and hip head of double transgenic transgenic mice. E-F: Non-cartilagenous 
tissues such as heart and lungs were not showing any blue staining. 	
As for the Aggrecan-driven vectors I wanted to evaluate the expression level of 
Timp3 in cartilage. As described in the previous chapter I micro-dissected the 
articular cartilage both from tibia plateau and femur condyles of 10-week old 
double transgenic mice injected with tamoxifen. RNA was extracted, purified and 
reverse-transcribed to produce cDNA library, as described in Methods (Chapter 
2.2). Relative levels of expression of Timp3 were evaluated and compared to the 
endogenous Hprt levels. Timp3 levels of expression in the UbCAla #38 mouse 
line were calculated to be 15-20 times upregulated compared to the control. 
These values are higher compared to the LLC1 #53 mouse line (Figure 5.5). 
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Figure 5.5: Timp3 upregulation in UbCAla #38 transgenic mice after tamoxifen 
administration. Real-time PCR analysis of Timp3 in mouse articular cartilage of 10-weeks old 
double transgenic mice and control mice (WT). Tamoxifen was administrated at 8-weeks of age. 
Y values represent fold difference of Timp3 expression compared to endogenous Hprt expression. 
n=4. P < 0.05. Error bars represent standard deviation. Hprt: hypoxanthine guanine 
phosphoribosyl transferase 
Finally TIMP-3 protein levels were investigated in mouse knees samples. Knees 
from 10-weeks old mice, injected with tamoxifen two weeks prior to collection. 
Epiphysis were dislodged from the underneath bone and collected. All four 
epiphysis from the lower limbs of each animal were pulled together and 
processed as described in Methods (Chapter 2.2). Western blot analysis on these 
samples showed an increase of TIMP-3 protein of 4-5 times (Figure 5.6). 
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Figure 5.6: Timp-3 protein is upregulation in UbCAla #38 transgenic mice after tamoxifen 
administration. Western blot analysis of TIMP-3 in mouse epiphysis of 10-weeks old double 
transgenic mice and control mice (WT). Tamoxifen was administrated at 8-weeks of age. Y 
values represent fold difference of TIMP-3 signal compared to endogenous Actin signal. n=4. P < 
0.05. Error bars represent standard deviation (SD). Upper: Representative Western Blot. Lower: 
representative statistical analysis. 
5.3 Discussion 
In this chapter I described how I generated a mouse model for general TIMP 
overexpression.  I decided to use the ubiquitin C promoter that would allow a 
virtually ubiquitous expression. Similarly to the vector described in Chapter 4, 
two vectors were designed to express TIMP-3 or [-1Ala]TIMP-3. Data on the 
localization of the β-galactosidase staining in HTB94 transfected cells, suggested 
that this promoter might provide a stronger expression of the transgene compared 
to the Aggrecan one. Transgenic mice were generated from both the plasmids, 
and only the ones expressing β-galactosidase at embryonic stage were kept. 
Moreover I selected only the ones that presented stronger blue staining. Among 
them the UbC [-1Ala]TIMP-3 #38 (UbCAla #38 in short) proved to be the most 
promising line, and I focused further studies on that one line.  
The rationale to employ a general promoter is to achieve expression in other 
tissue of the joint other than the articular cartilage itself. Expression of the 
transgene in the synovial membrane may allow the TIMP protein to be present in 
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the synovial fluid and increase the binding to the cartilage ECM. However a bias 
would be if the protein would be able to reach deeper layer of the tissue. On the 
other side if TIMP is expressed in the sub-chondral bone, it may help to protect 
the ECM in the deepest layers of the cartilage.  
In eukaryotic cells, not all the genetic information is readily available for 
transcription. It is known that in the nucleus DNA is organized in two structurally 
and transcriptionally different stati: heterochromatic and euchromathic. The first 
is usually associated with an “open” structure that allows the transcription 
machinery (including all the co-factors) to bind the target regions and promote 
gene expression; the latter is associated with “closed” structure and silencing of 
genes.  It has been proposed that genes and gene clusters may achieve regulatory 
autonomy by organization into chromatin domains that are maintained 
independently of their surroundings, through the establishment of chromatin 
boundaries. Chromatin boundaries are observed as a physical transition from 
transcriptionally repressive condensed chromatin to more permissive open 
chromatin structures. Such boundaries vary in position and would appear as a 
broad transition in chromatin states (fuzzy boundaries) when studying a 
population of cells. The lack of fixed boundaries is the basis of position-effect 
variegation (PEV), where the stochastic spread of heterochromatin formation 
results in the heritable silencing of a neighbouring gene.  Boundaries can be the 
result of a balance between countervailing chromatin opening and condensation 
processes that are nucleated at neighbouring gene loci. Such boundaries would 
not be fixed so large intergenic regions would be required to buffer a gene from 
its neighbours. The boundaries of heterochromatin domains can be fixed by the 
action of cis-regulatory elements. In some cases, these could be promoters or 
enhancers with specific characteristics that allow them to resist heterochromatin 
formation. Heterochromatin boundaries would be formed by autonomous 
elements known as insulators. Insulators can be defined as DNA elements that 
have a common ability to protect a gene from undesirable regulatory influences 
present in their chromosomal environment. There are at least five types of 
insulators in Drosophila that have been studied in details: the sequences flanking 
the heat shock hsp70 locus, the gypsy insulator (identified in the gypsy 
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retrotransposon), the Fab 8 insulator in the bithorax complex and the SF1 
insulator described in the Antennapedia complex. In vertebrates the most studied 
and characterized thus far is the CTCF-mediated insulator (as in the chicken β-
globin locus) that groups components and mechanisms of action of several of the 
invertebrates	ones	 (Barkess	and	West	2012). Randomly integrated transgenes that 
lack insulation tend to silence over time in culture, but transgenes shielded by 
barrier insulators may retain their expression, regardless of chromosomal 
position. Barrier insulators must be placed on both flanks of the transgene as 
chromosomal silencing can encroach from either direction. Studies on the 
chicken HS4 (cHS4) element from the β-globin locus control region displayed 
classic insulator activity: it insulates reporter genes from the activating effects of 
proximal enhancers, promotes uniform transgene expression in cell lines, and 
protects genes from chromosomal PEV in transgenic Drosophila and mice 
(Chung, Whiteley et al. 1993). The native cHS4 element is associated with a peak 
of histone hyperacetylation and other hallmarks of an “open” histone code, which 
in turn is thought to prevent the invasion of transcriptionally repressive 
heterochromatin from an adjoining region into the chicken β-globin locus.  
The PEV effect thus could affect the generation of transgenic mice. However 
being the site of integration of the transgene essentially a stochastic event, and 
being multiple integration events, a transgenic may escaper to PEV, as illustrated 
by the mouse lines described in chapters 3 and 4. Nevertheless I decided to 
include in a transgene meant for ubiquitous expression two tandem repeats of the 
cHS4 insulator, with the aim to potentially decrease PEV effect in this transgenic 
line.  
First I observed the expression of β-galactosidase in embryos. Blue staining was 
observed in the cartilaginous skeleton of embryos similarly to the Aggrecan-
driven mouse lines. However here staining was also present in skin tissues. Other 
organs were difficult to assess because the diffuse blue staining, however I would 
investigate them in older animals. When I investigated the adults, two weeks after 
tamoxifen administration, I could observe a strong staining in the articular 
cartilage of femur and tibia facing surface as well as in the hip head. Diffused 
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staining was observed in the sub-chondral bone, down to the growth plate that it 
is know to be positive to x-gal staining due osteoclast expressing β-galactosidase, 
as it is found positive also in wild-type mice (Kopp, Hooper et al. 2007). When 
spine and rib cage was stained blue staining was observed only in the ribs and 
intervertebral disks, but not in intercostal muscles. Internal organs such as heart, 
lungs or kidney were not stained. I did not investigated further the reason why 
those organs were not X-gal positive however , as diverged from the aim of the 
project. To assess the levels of Timp3 expression I extracted total mRNA from 
tibia and femur articular cartilage. Every sample contained cartilage from the 
lower hind of a single mouse, in order to highlight the variability among the 
single individuals. I observed in transgenic line UbCAla #38 an increase of 
Timp3 messenger of 15 times, a value clearly higher compared to the Aggrecan-
driven LLC1 #53. Interestingly being the mRNA extracted only from articular 
cartilage this result was not affected by other tissues that could express the 
transgene. Finally I investigated by Western Blotting analysis the TIMP-3 protein 
levels in femur and tibia epiphyses and found it was increased four times in the 
transgenic mice compared to the wild-type ones. 
Taken together those data shown that the generally speaking the Ubiquitin C 
promoter can be employed to target mouse articular cartilage, although 
expression may not be restricted to just that tissue. Role of other tissues of the 
knee joint need to be further investigated. However the expression levels of the 
transgene could be higher compared to the Aggrecan-driven one. Finally TIMP-3 
protein levels were found also increased. Discrepancy between mRNA and 
protein levels were expected as TIMP-3 is know to be regulated at both 
transcriptional and translational levels, but is also actively endocytosed, limiting 
its presence in the extracellular space.   
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Chapter 6  
Concluding remarks and future 
directions 
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6.1 Introduction 
Articular cartilage is fundamental for the functionality of the joint articulation. 
Although cartilage was shown to posses a certain degree of regeneration, major 
and continued insults can tilt the balance between catabolic and anabolic 
processes, leading to erosion of  the tissue. Among the pathologies that affect the 
articular cartilage, osteoarthritis (OA) is the most common, and the number of 
patients is increasing dramatically in the industrialized countries. Although OA in 
human is thought to be a multifactorial disease, deeply affected by style and 
quality of life, it has been shown experimentally in animal models that OA-like 
phenotype can be obtained by alteration of single specific genes. Particularly was 
observed that targeting genes coding for cartilage metalloproteinases such MMPs 
and ADAMTSs can prevent or delay experimental induced OA in animal models. 
Even more importantly was showed that targeting gene coding for endogenous 
inhibitors of those enzymes can predispose or accelerate the onset of the 
pathology. 
Metalloproteinases are implicated in the natural turnover of the extracellular 
macromolecules and collectively they can degrade all the major macromolecules 
of the extracellular matrix. Some of these enzymes are synthesized as pro-
enzymes, and generally they are soluble proteins. 
In cartilage ECM collagens are mostly represented by collagen type II and type X 
in the most inner region, close to the bone interface. Among the proteoglycans 
the most abundant is aggrecan. Available data suggest that while proteoglycan 
molecules are actively synthetized and degraded, the collagen components is 
more static, being deposed mostly during embryonic development. This evidence 
lead to the consequence that collagen structure cannot be deposed anew and once 
is degraded is lost. 
To date no therapeutic treatments that directly target OA are available, but not for 
lacking of candidates. Many research groups focused their efforts in generating 
synthetic approaches to controlling the level of MMP activity. Developing 
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proteinases inhibitors that are therapeutically active is very challenging as, in 
addition to ensuring that the molecule has the required potency, it must also be 
orally active, specific to the targeted enzyme family, and has no significant 
toxicity. These molecules are designed to target the catalytic pocket of the 
enzyme, limiting their action. The first generations of these inhibitors were 
broad-spectrum inhibitors and failed clinical trials. They were shown to produce 
musculoskeletal side effects characterized by joint stiffness, joint fibroplasias and 
accumulation of type I collagen in the affected joints, as well as mild anaemia 
and elevated levels of liver enzymes (Renkiewicz, Qiu et al. 2003, Georgiadis 
and Yiotakis 2008). Drug development programs are now exploring the use of 
selective inhibitors of proteinases rather than broad proteinases inhibition, aiming 
to reduce the side effects. However this may be a quite difficult task due to the 
high homology in the enzymes catalytic sites. An orally active MMP-13 inhibitor 
was shown in vivo in a rat meniscectomy model to exert chondro-protective 
effects and, interestingly, without observable musculoskeletal toxicity (Baragi, 
Becher et al. 2009). 
While MMPs are mostly targeting cartilage collagens, ADAMTSs (mostly -4 and 
-5) were shown to be responsible for most of aggrecan loss, according to the neo-
epitope resulting from aggrecan degradation, found in synovial joints of OA 
patients (Fosang, Stanton et al. 2003). In mice Adamts5 deficiency causes 
protection from OA, making the coded enzyme a key target for OA treatment. 
A different approach from design new inhibitory molecules is focusing on the 
endogenous inhibitors of cartilage catabolic enzymes. Increasing the local 
synthesis of TIMPs has been suggested to be an effective way of preventing 
articular tissue turnover and OA progression. Among the four mammalian 
TIMPs, TIMP-3 was shown to have high affinity inhibition toward both 
ADAMTS-4 and ADAMTS-5 (Kashiwagi, Tortorella et al. 2001) and MMPs. It 
has been shown that TIMP-3 deficiency in mice results in cartilage degradation 
similar to OA (Sahebjam, Khokha et al. 2007). Because its broad spectrum of 
activity TIMP-3 may not be the best candidate for therapeutic purpose, however 
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researchers have looked at engineering the TIMP-3 molecule to be selective to a 
specific MMP (Nagase and Brew 2002, Murphy and Nagase 2008). It has been 
recently demonstrated in vitro that mutating TIMP-3 adding an extra Alanine 
residue at the N-terminal, restricts the activity toward MMPs, maintaining 
inhibitory ability towards aggrecanases.  
6.2 Summary of current work and future prospectives 
The main aim of this study was to generate a tool to assess the potential of TIMP-
3 in altering the progression of experimentally induced osteoarthritis in mice. I 
chose TIMP-3 because its broad inhibitory activity and selectivity against 
cartilage-degrading enzymes, and thus a potential treatment for some type of OA. 
In this study I demonstrate that I could achieve cartilage-specific expression 
using Aggrecan regulatory elements, and that they are sufficient to deliver a 
stable and detectable amount of target protein in mouse knee articular cartilage. 
The first construct that I designed was used to generate a mouse cartilage-specific 
Cre-deleter. Although it was not the first of such systems present in literature 
(Henry, Jang et al. 2009), it was the first to use specific enhancer sequences 
found upstream to the Aggrecan gene. Unpublished work from our group 
suggested that different enhancer sequences could differently modulate the time-
space expression of the downstream gene. In my study I used the sequence that 
Han and Lefebvre designed as “A1” (Han and Lefebvre 2008). Henry and 
colleagues generated a different cartilage specific mouse line, opting to knock-in 
the Cre recombinase coding sequence downstream of the whole Aggrecan gene. 
Doing so they obtained at best only two copies per genome of the recombinase 
coding sequence. The recombination event requires very small amount of enzyme 
per cell, if not a single molecule, to be performed. It could be speculated that my 
system may have more copy per genome and thus possibly a higher affectivity, 
but comparing X-gal staining pattern from both embryos and adult knees does not 
highlight such differences. I also demonstrated that double transgenic mice 
(Col2a1-4xA1-CreERT2 x ROSA26R) are still prone to develop OA-like lesions in 
cartilage after DMM. What may be an interesting question is what happens to 
Leandro Lo Cascio  PhD Thesis 
 133 
aggrecan protein and gene expression after DMM surgery and during early OA. 
The Luciferase gene present in the construct is subjected to the same Aggrecan 
regulation thus I could detect bioluminescence emission in the mouse knee before 
and after DMM. The data recorded do not show large variations in the emission 
levels in a period of several weeks. Using fluorescence proteins may provide a 
more sensitive reading and accurate localization, but also require a more 
expensive hardware to be detected. In my experience the Kodak In Vivo FX Pro 
machine we currently employ, failed to detect mCherry protein fluorescence 
emission in adult mouse knee, although it could detect localized fluorescence 
from E16 embryos. Although some authors had shown Aggrecan expression in 
mouse brain, I never observed any staining in mouse embryos.  
Taking together all the data shown that this mouse line could be trustily used in 
study that depend on Cre recombination in cartilage, both in embryos that in 
adults. The DMM technique in adult, and very likely other surgical or mechanical 
techniques, could be used to investigate the osteoarthritis pathogenesis.  
In order to investigate the effect of TIMP-3 overexpression in an osteoarthritis 
model, I designed and generate a conditional TIMP-3-expressing mouse line. 
TIMP-3 is a potent endogenous inhibitor of matrix-degrading enzymes such as 
MMPs and ADAMTSs, with inhibitory activity concentration on the nanomolar. 
Those classes of enzymes have been associated with osteoarthritis both in mouse 
and human, and their regulation could be a potential treatment for OA. TIMP-3 
has been investigated because its broad activity range against metallo-
proteinases, however taking in account the failure of broad range drugs in OA 
treatment, some research group aimed to modify the protein sequence to restrict 
the activity to just one class of metalloproteinases or even single enzymes. It has 
been reported previously that a N-terminal reactive-site mutants of N-TIMP-3, 
[−N-te-TIMP-3 (N-TIMP-3 with an extra alanine residue appended to Cys1) is a 
poor MMP inhibitors but still retain inhibitory activity against ADAMs and 
ADAMTSs (Wei, Kashiwagi et al. 2005, Lim, Kashiwagi et al. 2010).  
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The conditional model I generated allows cartilage specific expression driven by 
the same Aggrecan enhancer elements previously used. I was thus quite confident 
on the specificity of the target delivery. The most important question was about 
the amount of TIMP-3 that would be delivered in cartilage, dependent on 
expression levels and protein turnover. As I mentioned earlier to obtain 
recombination in a Cre system, it is needed as little as a molecule per cells. The 
amount of TIMP-3 necessary to obtain inhibition of matrix molecules is unknown 
and can be assessed only empirically. A transgenic system has characteristic to 
harbour a higher number of copy compared to a knock-in, and thus lead to higher 
expression levels. Cartilage tissue proved to be difficult to investigate due to its 
composition of strongly charged proteoglycans and collagen fibers organized in a 
meshwork. I was able to optimize a protocol to extract mRNA from the thin layer 
of mouse articular cartilage, and observe about 4-fold increase compared to 
control. I failed to detect TIMP-3 protein in articular cartilage by Western Blot. 
Reason maybe due to the small amount of sample that did not allow stronger 
processing to separate the highly charged proteins. However I detected an 
increase in protein signal by Immunofluorescence of mouse knee sections.  As I 
already mentioned the amount of protein in the cartilage is of paramount 
importance, and expression is not the only factor that may limit the inhibitory 
activity. It has been shown by Scilabra and co-workers that TIMP-3 is actively 
internalized by two different pathways (Scilabra, Troeberg et al. 2013). It is not 
clear however if the internalization can boost a self-limiting loop to reduce the 
amount or TIMP-3-scavenger proteins on the cell surface. Data so obtained 
strongly suggested that the model generated is able to deliver TIMP-3 in adult 
mouse articular cartilage. 
The obvious future plan would be to perform DMM surgery on this mouse model 
to challenge the hypothesis that TIMP-3 delivered in mouse cartilage could 
ameliorate the OA outcome. However several points need to be taken in account:  
1) Tamoxifen administration. 
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a. To obtain the maximum amount of TIMP-3 it could be speculated that 
tamoxifen has to be given as earlier as possible but after full mouse 
development to avoid structural defects. 
b. Overexpressing TIMP-3 before the OA onset could lead to positive results in 
terms of cartilage protection, but would not resemble any real clinical fact. 
Thus will be required to evaluate the effect of tamoxifen administration at the 
same time and even after the DMM. 
2) TIMP-3 delivery 
a. In my model chondrocytes are induced to express an exogenous protein, 
providing a proof of concept. However an alternative delivery method have to 
be devised. In my group we are working in order to produce both Adenoviral 
and Lentiviral vectors to overexpress TIMP-3. 
b. Viral vector-based delivery in articular cartilage is affected by several 
technical problems. First, mouse articular capsule is extremely small and only 
minute amount of volume can be injected. Using rats or rabbits as animal 
model may help on this point. Second, both adeno- or lenti- viruses have to 
travel across the surface of the joint to approach articular chondrocytes (and 
probably synoviocytes). Deeper chondrocytes could be infected at very low 
rates or not at all. Increasing the amount of virus injected however can 
increase also the toxicity on cells closer to the surface. Finally, adenovirus 
vectors produce a temporary increase in the expression of the target protein, 
and we could speculate that more injections could be necessary; on the other 
hand lentivirus vectors integrate in the DNA of the target cell, maintaining a 
more stable expression. Articular chondrocytes posses a relatively low 
proliferating ratio and movement ability, both are quality that could enhance 
the safety of viral vector-based gene therapy.  
Many studies are pointing out that direct therapeutic gene transfer could be a 
promising tool to treat articular cartilage defects. Very recently it has been shown 
the successful ability of a recombinant adeno-associated virus (rAAV) insulin-
like growth factor I (IGF-I) vector to improve the early repair of cartilage lesions 
in rabbit in vivo (Cucchiarini and Madry 2014). 
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TIMP-3 and its mutant such the [−1A]TIMP-3 should be strongly investigated as 
promising target to balance the enzymatic degradation of cartilage 
macromolecules.  
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